Dose, volume, and function relationships in parotid sali and intensity-modulated irradiation of head and neck c

International Journal of Radiation Oncology Biology Physics 45, 577-587

DOI: 10.1016/s0360-3016(99)00247-3

Citation Report

#	Article	IF	CITATIONS
1	Comments. International Journal of Radiation Oncology Biology Physics, 2000, 47, 1458-1459.	0.4	27
3	A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. International Journal of Radiation Oncology Biology Physics. 2000. 48. 7-16.	0.4	1,222
4	Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California–San Francisco experience. International Journal of Radiation Oncology Biology Physics, 2000, 48, 711-722.	0.4	243
5	Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1117-1126.	0.4	344
6	Three-dimensional Conformal Radiation Therapy. Surgical Oncology Clinics of North America, 2000, 9, 455-467.	0.6	5
7	Natura History an Prevention of Radiation Injury. Advances in Dental Research, 2000, 14, 57-61.	3.6	21
8	Partial irradiation of the parotid gland. Seminars in Radiation Oncology, 2001, 11, 234-239.	1.0	78
9	The efficacy of Xialine \hat{A}^{\otimes} in patients with xerostomia resulting from radiotherapy for head and neck cancer: a pilot-study. Radiotherapy and Oncology, 2001, 59, 157-160.	0.3	55
10	Optimisation of radiotherapy for carcinoma of the parotid gland: a comparison of conventional, three-dimensional conformal, and intensity-modulated techniques. Radiotherapy and Oncology, 2001, 60, 163-172.	0.3	81
11	Parotid and submandibular/sublingual salivary flow during high dose radiotherapy. Radiotherapy and Oncology, 2001, 61, 271-274.	0.3	155
12	Evaluation of a leaf position optimization tool for intensity modulated radiation therapy of head and neck cancer. Radiotherapy and Oncology, 2001, 61, 281-286.	0.3	22
13	Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiotherapy and Oncology, 2001, 61, 275-280.	0.3	306
14	Prise en charge des mucites aprÃ"s radiothérapie des cancers des voies aérodigestives supérieures. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2001, 5, 121s-130s.	0.6	6
15	Intensity Modulation Techniques for Improvement of Normal Tissue Tolerance., 2001, 37, 163-173.		2
16	Recent Advances in Radiotherapy for Head and Neck Cancers. Ear, Nose and Throat Journal, 2001, 80, 704-719.	0.4	4
17	The utility of SPECT in determining the relationship between radiation dose and salivary gland dysfunction after radiotherapy. Nuclear Medicine Communications, 2001, 22, 225-231.	0.5	47
18	Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. International Journal of Radiation Oncology Biology Physics, 2001, 49, 623-632.	0.4	271
19	A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. International Journal of Radiation Oncology Biology Physics, 2001, 49, 907-916.	0.4	549

#	ARTICLE	IF	Citations
20	Calculation of the uncertainty in complication probability for various dose–response models, applied to the parotid gland. International Journal of Radiation Oncology Biology Physics, 2001, 50, 147-158.	0.4	50
21	Potential role of intensity-modulated radiotherapy in the treatment of tumors of the maxillary sinus. International Journal of Radiation Oncology Biology Physics, 2001, 51, 579-588.	0.4	67
22	An anatomy-based beam segmentation tool for intensity-modulated radiation therapy and its application to head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2001, 51, 849-859.	0.4	95
23	The effect of setup uncertainty on normal tissue sparing with IMRT for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2001, 51, 1400-1409.	0.4	108
24	Leaf position optimization for step-and-shoot IMRT. International Journal of Radiation Oncology Biology Physics, 2001, 51, 1371-1388.	0.4	94
25	Tissue/dose compensation to reduce toxicity from combined radiation and chemotherapy for advanced head and neck cancers. International Journal of Cancer, 2001, 96, 61.	2.3	29
26	Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists. British Journal of Cancer, 2001, 85, 1055-1063.	2.9	117
27	Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Supportive Care in Cancer, 2001, 9, 247-257.	1.0	86
28	Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2001, 50, 695-704.	0.4	661
29	The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. International Journal of Radiation Oncology Biology Physics, 2001, 51, 332-343.	0.4	184
30	Qantitative dose-volume response analysis of changes in parotid gland function after radiotheraphy in the head-and-neck region. International Journal of Radiation Oncology Biology Physics, 2001, 51, 938-946.	0.4	253
32	Uncertainties in model-based outcome predictions for treatment planning. International Journal of Radiation Oncology Biology Physics, 2001, 51, 1389-1399.	0.4	32
33	Modeling the effects of inhomogeneous dose distributions in normal tissues. Seminars in Radiation Oncology, 2001, 11, 197-209.	1.0	46
34	Partial irradiation of the lung. Seminars in Radiation Oncology, 2001, 11, 247-258.	1.0	65
35	Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncology, 2001, 37, 84-93.	0.8	185
36	Using HSV-Thymidine Kinase for Safety in an Allogeneic Salivary Graft Cell Line. Tissue Engineering, 2001, 7, 405-413.	4.9	13
37	Effect of multileaf collimator leaf width on physical dose distributions in the treatment of CNS and head and neck neoplasms with intensity modulated radiation therapy. Medical Physics, 2002, 29, 1116-1119.	1.6	75
38	IMRT in the treatment of head and neck cancer: is the present already the future?. Expert Review of Anticancer Therapy, 2002, 2, 297-308.	1.1	10

3

#	Article	IF	CITATIONS
39	Saliva Flow, pH, Buffer Capacity, and Colonization by <i>Streptococcus mutans</i> during and after Radical Radiotherapy of Head and Neck Tumours. Oto-rhino-laryngologia Nova, 2002, 12, 137-144.	0.0	O
40	Maintained Salivary Function after Brachytherapy in Patients with Head and Neck Carcinomas - Evaluation Using Quantitative Salivary Gland Scintigraphy. Acta Oncol \tilde{A}^3 gica, 2002, 41, 684-688.	0.8	5
41	Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose–volume histograms and normal tissue complication probability. Radiotherapy and Oncology, 2002, 63, 249-255.	0.3	70
42	High-dose, high-precision treatment options for boosting cancer of the nasopharynx. Radiotherapy and Oncology, 2002, 63, 67-74.	0.3	38
43	Preservation of parotid function with uncomplicated conformal radiotherapy. Radiotherapy and Oncology, 2002, 63, 203-211.	0.3	115
44	Comparison of radiosensitivity of rat parotid and submandibular glands after different radiation schedules. Radiotherapy and Oncology, 2002, 63, 321-328.	0.3	94
45	The dose to the parotid glands with IMRT for oropharyngeal tumors: the effect of reduction of positioning margins. Radiotherapy and Oncology, 2002, 64, 197-204.	0.3	55
46	Sensori-neural hearing loss after radiotherapy for nasopharyngeal carcinoma: individualized risk estimation. Radiotherapy and Oncology, 2002, 65, 9-16.	0.3	128
47	Intensity modulated arc deliveries approximated by a large number of fixed gantry position sliding window dynamic multileaf collimator fields. Medical Physics, 2002, 29, 2359-2365.	1.6	21
49	Tissue Compatibility of Two Biodegradable Tubular Scaffolds Implanted Adjacent to Skin or Buccal Mucosa in Mice. Tissue Engineering, 2002, 8, 649-659.	4.9	39
50	Dosimetric verification of inverse planned step and shoot multileaf collimator fields from a commercial treatment planning system. Journal of Applied Clinical Medical Physics, 2002, 3, 97-109.	0.8	11
51	Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Seminars in Radiation Oncology, 2002, 12, 20-25.	1.0	75
52	Intensity-modulated radiation therapy for head and neck cancer: Emphasis on the selection and delineation of the targets. Seminars in Radiation Oncology, 2002, 12, 238-249.	1.0	209
53	Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: Subcutaneous amifostine and computed tomography-based target delineation. Seminars in Oncology, 2002, 29, 63-70.	0.8	2
54	Using technology to decrease xerostomia for head and neck cancer patients treated with radiation therapy. Seminars in Oncology, 2002, 29, 71-79.	0.8	2
55	The influence of clinical factors on human stimulated parotid flow rate in cancer and other patients. Oral Oncology, 2002, 38, 291-295.	0.8	18
56	Intensity modulated radiation therapy for oropharyngeal and oral cavity tumors: clinical use and experience. Oral Oncology, 2002, 38, 597-604.	0.8	53
57	Patients with head and neck cancer cured by radiation therapy: A survey of the dry mouth syndrome in long-term survivors. Head and Neck, 2002, 24, 737-747.	0.9	166

#	Article	IF	Citations
58	Quality of life of nasopharyngeal carcinoma patients. Cancer, 2002, 94, 1012-1017.	2.0	60
59	Current therapy for malignant mesothelioma. Current Oncology Reports, 2002, 4, 305-313.	1.8	12
60	Sparing of Contralateral Major Salivary Glands Has a Significant Effect on Oral Health in Patients Treated with Radical Radiotherapy of Head and Neck Tumors. Strahlentherapie Und Onkologie, 2002, 178, 722-726.	1.0	23
61	Management of oral disease prior to radiation therapy. Supportive Care in Cancer, 2002, 10, 40-43.	1.0	71
62	Clinical aspects of IMRT for head-and-neck cancer. Medical Dosimetry, 2002, 27, 99-104.	0.4	41
63	Xerostomia and the Geriatric Patient. Journal of the American Geriatrics Society, 2002, 50, 535-543.	1.3	311
64	Intensity-modulated radiation therapy: First reported treatment in Australasia. Journal of Medical Imaging and Radiation Oncology, 2002, 46, 285-289.	0.6	9
65	Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. International Journal of Radiation Oncology Biology Physics, 2002, 52, 224-235.	0.4	342
66	Role of endocavitary brachytherapy with or without chemotherapy in cancer of the nasopharynx. International Journal of Radiation Oncology Biology Physics, 2002, 52, 755-768.	0.4	35
67	Is uniform target dose possible in IMRT plans in the head and neck?. International Journal of Radiation Oncology Biology Physics, 2002, 52, 1159-1172.	0.4	70
68	Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. International Journal of Radiation Oncology Biology Physics, 2002, 53, 12-22.	0.4	924
69	Determination and delineation of nodal target volumes for head-and-neck cancer based on patterns of failure in patients receiving definitive and postoperative IMRT. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1174-1184.	0.4	227
70	A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2002, 54, 9-13.	0.4	93
71	The role Of intensity-modulated radiotherapy in the treatment of parotid tumors. International Journal of Radiation Oncology Biology Physics, 2002, 52, 729-738.	0.4	63
72	Analysis of radiation-induced liver disease using the Lyman NTCP model. International Journal of Radiation Oncology Biology Physics, 2002, 53, 810-821.	0.4	688
73	Influence of dose calculation model on treatment plan evaluation in conformal radiotherapy: a three-case study. Medical Dosimetry, 2002, 27, 51-57.	0.4	18
74	Chemotherapy and high–dose-rate brachytherapy in the management of advanced cancers of the nasopharynx. Brachytherapy, 2002, 1, 11-20.	0.2	10
75	Treatment of xerostomia following radiotherapy: does age matter?. Supportive Care in Cancer, 2002, 10, 505-508.	1.0	18

#	Article	IF	CITATIONS
76	Xerostomia and hypofunction of the salivary glands in cancer therapy. Supportive Care in Cancer, 2003, 11, 207-225.	1.0	155
77	Salivary Gland Sparing and Improved Target Irradiation by Conformal and Intensity Modulated Irradiation of Head and Neck Cancer. World Journal of Surgery, 2003, 27, 832-837.	0.8	173
78	Intensit�tsmodulierte Strahlentherapie. Onkologe, 2003, 9, 315-327.	0.7	2
79	How should we measure and report radiotherapy-induced xerostomia?. Seminars in Radiation Oncology, 2003, 13, 226-234.	1.0	135
80	Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data. Seminars in Oncology, 2003, 30, 96-100.	0.8	11
81	Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients. Cancer Detection and Prevention, 2003, 27, 305-310.	2.1	58
82	Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. International Journal of Radiation Oncology Biology Physics, 2003, 55, 768-775.	0.4	138
83	Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: dosimetric results. International Journal of Radiation Oncology Biology Physics, 2003, 56, 573-585.	0.4	263
84	Quality of life after parotid-sparing IMRT for head-and-neck cancer: A prospective longitudinal study. International Journal of Radiation Oncology Biology Physics, 2003, 57, 61-70.	0.4	321
85	Potential of intensity-modulated radiotherapy to escalate doses to head-and-neck cancers: What is the maximal dose?. International Journal of Radiation Oncology Biology Physics, 2003, 57, 673-682.	0.4	21
86	Swallowing dysfunctionâ€"preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: A critical review. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1219-1230.	0.4	190
87	Techniki dynamiczne generujÄ…ce zróŽnicowany rozkÅ,ad dawki promieniowania w radioterapii. Reports of Practical Oncology and Radiotherapy, 2003, 8, 9-83.	0.3	1
89	Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation. International Journal of Radiation Oncology Biology Physics, 2003, 56, 145-157.	0.4	279
90	Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. International Journal of Radiation Oncology Biology Physics, 2003, 56, 136-144.	0.4	65
91	Intensity modulated radiotherapy treatment planning for dynamic multileaf collimator delivery: influence of different parameters on dose distributions. Radiotherapy and Oncology, 2003, 66, 19-28.	0.3	21
92	Systematic set-up errors for IMRT in the head and neck region: effect on dose distribution. Radiotherapy and Oncology, 2003, 66, 303-311.	0.3	44
93	Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. Radiotherapy and Oncology, 2003, 66, 313-321.	0.3	49
94	Optimisation of conformal radiation therapy by intensity modulation. Radiotherapy and Oncology, 2003, 66, 291-302.	0.3	47

#	Article	IF	CITATIONS
95	Estimation of parameters of dose–volume models and their confidence limits. Physics in Medicine and Biology, 2003, 48, 1863-1884.	1.6	23
96	O <scp>ral</scp> S <scp>equelae of</scp> H <scp>ead and</scp> N <scp>eck</scp> R <scp>adiotherapy</scp> . Critical Reviews in Oral Biology and Medicine, 2003, 14, 199-212.	4.4	680
97	A comparison of forward and inverse treatment planning for intensity-modulated radiotherapy of head and neck cancer. Radiotherapy and Oncology, 2003, 69, 251-258.	0.3	22
98	Importance of accurate dose calculations outside segment edges in intensity modulated radiotherapy treatment planning. Radiotherapy and Oncology, 2003, 69, 305-314.	0.3	16
99	Segmental IMRT for oropharyngeal cancer in a clinical setting. Radiotherapy and Oncology, 2003, 69, 259-266.	0.3	13
100	Structural and functional injury in minipig salivary glands following fractionated exposure to 70 Gy of ionizing radiation: an animal model for human radiation-induced salivary gland injury. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2003, 96, 267-274.	1.6	92
103	Intensity-modulated radiotherapy optimization with gEUD-guided doseÂvolume objectives. Physics in Medicine and Biology, 2003, 48, 279-291.	1.6	59
104	P <scp>revention and</scp> T <scp>reatment of the</scp> C <scp>onsequences of</scp> H <scp>ead and</scp> N <scp>eck</scp> R <scp>adiotherapy</scp> . Critical Reviews in Oral Biology and Medicine, 2003, 14, 213-225.	4.4	309
105	The Changes in Irradiated Salivary Gland Function of Patients with Head and Neck Tumors Treated with Radiotherapy. Japanese Journal of Clinical Oncology, 2003, 33, 336-340.	0.6	18
106	Title is missing!. Nuclear Medicine Communications, 2003, 24, 845-852.	0.5	0
107	Nuclear medicine in the prediction and detection of radiation associated normal tissue damage of kidney, brain, bone marrow and salivary glands. Nuclear Medicine Communications, 2003, 24, 845-852.	0.5	3
108	Feasibility of Intensity-Modulated Radiation Therapy in the Treatment of Advanced Cervical Chordoma. Tumori, 2003, 89, 298-304.	0.6	11
109	Combination of Chemotherapy with Radiation for Head and Neck Cancer., 2003,, 445-460.		0
110	Clinical use of intensity-modulated radiotherapy: part I. British Journal of Radiology, 2004, 77, 88-96.	1.0	42
111	Can Photon IMRT be improved by combination with mixed electron and photon techniques?. Acta $Oncol\tilde{A}^3$ gica, 2004, 43, 727-735.	0.8	32
112	Intensity-modulated radiation therapy for head and neck cancer. Expert Review of Anticancer Therapy, 2004, 4, 425-434.	1.1	10
113	Practical experience with intensity-modulated radiotherapy. British Journal of Radiology, 2004, 77, 3-14.	1.0	26
114	Dosimetric study of optimal beam number and arrangement for treatment of nasopharyngeal carcinoma with intensity-modulated radiation therapy. Journal of Medical Imaging and Radiation Oncology, 2004, 48, 45-50.	0.6	6

#	Article	IF	Citations
115	'Boomerang' technique: An improved method for conformal treatment of locally advanced nasopharyngeal cancer. Journal of Medical Imaging and Radiation Oncology, 2004, 48, 170-180.	0.6	8
116	Level II lymph nodes and radiation-induced xerostomia. International Journal of Radiation Oncology Biology Physics, 2004, 58, 124-131.	0.4	41
117	Rotterdam and Brussels CT-based neck nodal delineation compared with the surgical levels as defined by the American Academy of Otolaryngology–Head and Neck Surgery. International Journal of Radiation Oncology Biology Physics, 2004, 58, 113-123.	0.4	72
118	Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Seminars in Oncology, 2004, 31, 8-12.	0.8	31
119	A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Seminars in Oncology, 2004, 31, 25-28.	0.8	44
120	Radiotherapy-induced salivary dysfunction. Seminars in Oncology, 2004, 31, 29-36.	0.8	34
121	Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Seminars in Radiation Oncology, 2004, 14, 103-109.	1.0	62
122	Intensity-modulated radiation therapy in head and neck squamous cell carcinoma: an adaptation of 2-dimensional concepts or a reconsideration of current clinical practice. Seminars in Radiation Oncology, 2004, 14, 110-120.	1.0	15
123	Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1440-1450.	0.4	484
124	Clinical aspects of normal tissue complication probability. Reports of Practical Oncology and Radiotherapy, 2004, 9, 261-267.	0.3	2
125	Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. International Journal of Radiation Oncology Biology Physics, 2004, 58, 175-184.	0.4	137
126	Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma. Cancer, 2004, 101, 1584-1593.	2.0	219
127	Scintigraphic assessment of early and late parotid gland function after radiotherapy for head-and-neck cancer: a prospective study of dose–volume response relationships. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1451-1460.	0.4	82
128	Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. International Journal of Radiation Oncology Biology Physics, 2004, 59, 28-42.	0.4	297
129	Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. International Journal of Radiation Oncology Biology Physics, 2004, 59, 960-970.	0.4	643
130	Phenomenologic model describing flow reduction for parotid gland irradiation with intensity-modulated radiotherapy: Evidence of significant recovery effect. International Journal of Radiation Oncology Biology Physics, 2004, 60, 178-185.	0.4	21
131	Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: Il—clinical results. International Journal of Radiation Oncology Biology Physics, 2004, 60, 374-387.	0.4	137
132	Intensity-modulated radiation therapy. Current Problems in Cancer, 2004, 28, 47-84.	1.0	6

#	ARTICLE	IF	CITATIONS
133	Oral Complications of Radiotherapy in Head and Neck Cancer. American Journal of Cancer, 2004, 3, 291-298.	0.4	1
134	Metastases in Head and Neck Cancer. , 2004, , .		17
135	Clinical knowledge-based inverse treatment planning. Physics in Medicine and Biology, 2004, 49, 5101-5117.	1.6	41
136	Prevention and Treatment of Salivary Gland Hypofunction Related to Head and Neck Radiation Therapy and Chemotherapy. Supportive Cancer Therapy, 2004, 1, 111-118.	0.3	17
139	Potential outcomes of modalities and techniques in radiotherapy for patients with hypopharyngeal carcinoma. Radiotherapy and Oncology, 2004, 72, 129-138.	0.3	23
140	Radiotherapy for nasopharyngeal carcinomaâ€"transition from two-dimensional to three-dimensional methods. Radiotherapy and Oncology, 2004, 73, 163-172.	0.3	60
141	11C-methionine PET, a novel method for measuring regional salivary gland function after radiotherapy of head and neck cancer. Radiotherapy and Oncology, 2004, 73, 289-296.	0.3	34
142	Dose–response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiotherapy and Oncology, 2004, 73, 297-306.	0.3	85
143	A TCP-NTCP estimation module using DVHs and known radiobiological models and parameter sets. Journal of Applied Clinical Medical Physics, 2004, 5, 50-63.	0.8	95
144	Intensity-Modulated Radiation Therapy in Head and Neck Cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 415-423.	0.6	54
145	Intensity-modulated radiation therapy in the management of head and neck cancer. Current Opinion in Oncology, 2005, 17, 231-235.	1.1	9
146	The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. International Journal of Radiation Oncology Biology Physics, 2005, 61, 779-788.	0.4	255
147	Use of principal component analysis to evaluate the partial organ tolerance of normal tissues to radiation. International Journal of Radiation Oncology Biology Physics, 2005, 62, 829-837.	0.4	57
148	Long-term parotid gland function after radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 62, 659-664.	0.4	106
149	Volume effects and region-dependent radiosensitivity of the parotid gland. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1090-1095.	0.4	74
150	Dose–volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1055-1069.	0.4	242
151	Effect of patient setup errors on simultaneously integrated boost head and neck IMRT treatment plans. International Journal of Radiation Oncology Biology Physics, 2005, 63, 422-433.	0.4	80
152	Matched case–control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: Initial report. International Journal of Radiation Oncology Biology Physics, 2005, 63, 725-731.	0.4	169

#	ARTICLE	IF	CITATIONS
153	Comparing step-and-shoot IMRT with dynamic helical tomotherapy IMRT plans for head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1535-1539.	0.4	102
154	A comparison of mean parotid gland dose with measures of parotid gland function after radiotherapy for head-and-neck cancer: Implications for future trials. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1006-1009.	0.4	56
155	Structural and functional characteristics of irradiation damage to parotid glands in the miniature pig. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1510-1516.	0.4	62
156	Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: Dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. International Journal of Radiation Oncology Biology Physics, 2005, 63, 274-281.	0.4	99
157	Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology Biology Physics, 2005, 63, 985-990.	0.4	151
158	Rebuttal to Drs. Hu and Harrison. Brachytherapy, 2005, 4, 7-8.	0.2	O
159	Counterpoint. Brachytherapy, 2005, 4, 5-7.	0.2	5
160	Parotid-sparing Radiotherapy: Does it Really Reduce Xerostomia?. Clinical Oncology, 2005, 17, 610-617.	0.6	13
162	ConPas: a 3-D Conformal Parotid Gland-Sparing Irradiation Technique for Bilateral Neck Treatment as an Alternative to IMRT. Strahlentherapie Und Onkologie, 2005, 181, 673-682.	1.0	24
163	Dose volume histogram comparison between ADAC Pinnacle and Nomos Corvus systems for IMRT. Australasian Physical and Engineering Sciences in Medicine, 2005, 28, 1-7.	1.4	4
164	Intensity-modulated radiotherapy: Is xerostomia still prevalent?. Current Oncology Reports, 2005, 7, 131-136.	1.8	33
165	Effects of EGF and bFGF on Irradiated Parotid Glands. Annals of Biomedical Engineering, 2005, 33, 685-695.	1.3	32
166	Costlets: A Generalized Approach to Cost Functions for Automated Optimization of IMRT Treatment Plans. Optimization and Engineering, 2005, 6, 421-448.	1.3	49
167	â—ª Future Physiologic Research. , 2005, , .		0
169	Intensity-modulated radiation therapy for head and neck cancer. Expert Review of Anticancer Therapy, 2005, 5, 515-521.	1.1	9
170	A Bayesian mixture model relating dose to critical organs and functional complication in 3D conformal radiation therapy. Biostatistics, 2005, 6, 615-632.	0.9	13
171	A Comparative Study on the Protection Profile of Lidocaine, Amifostine, and Pilocarpin on the Parotid Gland during Radiotherapy. Cancer Research, 2005, 65, 10486-10493.	0.4	17
172	Gustatory Stimulation Changes the Apparent Diffusion Coefficient of Salivary Glands: Initial Experience. Radiology, 2005, 235, 629-634.	3.6	52

#	Article	IF	CITATIONS
173	Automatic selection of non-coplanar beam directions for three-dimensional conformal radiotherapy. British Journal of Radiology, 2005, 78, 316-327.	1.0	32
174	Intensity-modulated radiation therapy: emerging cancer treatment technology. British Journal of Cancer, 2005, 92, 1819-1824.	2.9	78
175	Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiotherapy and Oncology, 2005, 74, 251-258.	0.3	137
176	Parotid gland-sparing 3-dimensional conformal radiotherapy results in less severe dry mouth in nasopharyngeal cancer patients: A dosimetric and clinical comparison with conventional radiotherapy. Radiotherapy and Oncology, 2005, 75, 204-209.	0.3	30
177	Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: Equivalence between step-and-shoot and sliding window techniques. Radiotherapy and Oncology, 2005, 77, 148-156.	0.3	41
178	Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?. Radiotherapy and Oncology, 2005, 77, 164-171.	0.3	116
179	Three-dimensional IMRT verification with a flat-panel EPID. Medical Physics, 2005, 32, 600-612.	1.6	93
180	Health benefits of saliva: a review. Journal of Dentistry, 2005, 33, 223-233.	1.7	518
181	Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma: state of the art and future challenges. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2005, 9, 42-50.	0.6	18
182	Derivative-free generation and interpolation of convex Pareto optimal IMRT plans. Physics in Medicine and Biology, 2006, 51, 6349-6369.	1.6	48
184	Radiation-related damage to dentition. Lancet Oncology, The, 2006, 7, 326-335.	5.1	293
185	Impact of the type of imaging modality on target volumes delineation and dose distribution in pharyngo-laryngeal squamous cell carcinoma: comparison between pre- and per-treatment studies. Radiotherapy and Oncology, 2006, 78, 291-297.	0.3	119
186	Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiotherapy and Oncology, 2006, 78, 276-282.	0.3	134
187	Individual radiation response of parotid glands investigated by dynamic 11C-methionine PET. Radiotherapy and Oncology, 2006, 78, 262-269.	0.3	33
188	Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiotherapy and Oncology, 2006, 78, 270-275.	0.3	137
189	[18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiotherapy and Oncology, 2006, 79, 249-258.	0.3	159
190	The impact of dental metal artifacts on head and neck IMRT dose distributions. Radiotherapy and Oncology, 2006, 79, 198-202.	0.3	58
191	Dynamic intensity-modulated non-coplanar arc radiotherapy (INCA) for head and neck cancer. Radiotherapy and Oncology, 2006, 81, 151-157.	0.3	29

#	Article	IF	CITATIONS
192	Intensity-Modulated Radiotherapy in the Standard Management of Head and Neck Cancer: Promises and Pitfalls. Journal of Clinical Oncology, 2006, 24, 2618-2623.	0.8	187
193	Chemoradiation Therapy: The Evolving Role in Head and Neck Cancer and Its Application to Oral Cavity Tumors. Oral and Maxillofacial Surgery Clinics of North America, 2006, 18, 605-614.	0.4	1
194	Dramatic and prolonged decrease of whole salivary secretion in nasopharyngeal carcinoma patients treated with radiotherapy. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2006, 101, 322-327.	1.6	25
195	Intensity modulated radiotherapy: advantages, limitations and future development. Biomedical Imaging and Intervention Journal, 2006, 2, e19.	0.5	47
196	Target Coverage in Head and Neck Cancer Treated with Intensity-Modulated Radiotherapy: A Comparison between Conventional and Conformal Techniques. Tumori, 2006, 92, 503-510.	0.6	11
197	Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. International Journal of Oncology, 2006, 28, 1141.	1.4	5
198	Assessment of Salivary Function Change in Nasopharyngeal Carcinoma Treated by Parotid-Sparing Radiotherapy. Cancer Journal (Sudbury, Mass), 2006, 12, 494-500.	1.0	14
199	Effect of Regression of Enlarged Neck Lymph Nodes on Radiation Doses Received by Parotid Glands During Intensity-Modulated Radiotherapy for Head and Neck Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 600-605.	0.6	47
200	Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. Current Opinion in Oncology, 2006, 18, 266-270.	1.1	31
201	3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing. Radiation Oncology, 2006, 1, 18.	1.2	5
202	Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. Oral Diseases, 2006, 12, 297-300.	1.5	30
203	Can Dose Reduction to One Parotid Gland Prevent Xerostomia? — A Feasibility Study for Locally Advanced Head and Neck Cancer Patients Treated with Intensity-modulated Radiotherapy. Clinical Oncology, 2006, 18, 497-504.	0.6	33
204	Secondary radiation damage as the main cause for unexpected volume effects: A histopathologic study of the parotid gland. International Journal of Radiation Oncology Biology Physics, 2006, 64, 98-105.	0.4	64
205	Spinal cord planning risk volumes for intensity-modulated radiation therapy of head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2006, 64, 321-325.	0.4	11
206	Simultaneous modulated accelerated radiation therapy in the treatment of nasopharyngeal cancer: A local center's experience. International Journal of Radiation Oncology Biology Physics, 2006, 66, S40-S46.	0.4	39
207	Three-dimensional conformal radiotherapy for locally advanced (Stage II and worse) head-and-neck cancer: Dosimetric and clinical evaluation. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1036-1043.	0.4	16
208	Parotid-sparing intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma: Preserved parotid function after IMRT on quantitative salivary scintigraphy, and comparison with historical data after conventional radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 66, 454-461.	0.4	63
209	Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 445-453.	0.4	148

#	ARTICLE	IF	Citations
210	Geometric factors influencing dosimetric sparing of the parotid glands using IMRT. International Journal of Radiation Oncology Biology Physics, 2006, 66, 296-304.	0.4	71
211	Is mask-based stereotactic head-and-neck fixation as precise as stereotactic head fixation for precision radiotherapy?. International Journal of Radiation Oncology Biology Physics, 2006, 66, S61-S66.	0.4	19
212	Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial. International Journal of Radiation Oncology Biology Physics, 2006, 66, 981-991.	0.4	654
213	Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 66, 975-980.	0.4	127
214	Risk-adaptive optimization: Selective boosting of high-risk tumor subvolumes. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1528-1542.	0.4	57
215	How to reduce radiation-related toxicity in patients with cancer of the head and neck. Current Oncology Reports, 2006, 8, 140-145.	1.8	20
216	Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly. Cancer, 2006, 107, 544-553.	2.0	45
217	Radiation-induced xerostomia in patients with head and neck cancer. Cancer, 2006, 107, 2525-2534.	2.0	325
218	Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head and Neck, 2006, 28, 64-73.	0.9	138
219	Preservation of quality of life after intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: Results of a prospective longitudinal study. Head and Neck, 2006, 28, 712-722.	0.9	62
221	Factors Influencing the Parotid Function in Nasopharyngeal Carcinoma Treated with Parotid-Sparing Radiotherapy. Japanese Journal of Clinical Oncology, 2006, 36, 626-631.	0.6	11
222	Radiotherapeutic management of locally advanced head and neck cancer. Expert Review of Anticancer Therapy, 2006, 6, 405-417.	1.1	19
223	IMRT for Carcinomas of the Nasopharynx. , 2006, , 319-334.		0
224	New Developments in Intensity Modulated Radiation Therapy. Technology in Cancer Research and Treatment, 2006, 5, 451-464.	0.8	15
225	Oral Complications of Cancer Therapy. , 2006, , 1349-1362.		0
226	IMRT for Carcinomas of the Oropharynx and Oral Cavity. , 2006, , 301-317.		0
227	Dry Mouth and Its Effects on the Oral Health of Elderly People. Journal of the American Dental Association, 2007, 138, S15-S20.	0.7	264
228	Patient assessed symptoms are poor predictors of objective findings. Results from a cross sectional study in patients treated with radiotherapy for pharyngeal cancer. Acta Oncol \tilde{A}^3 gica, 2007, 46, 1159-1168.	0.8	59

#	Article	IF	CITATIONS
229	Measuring side effects after radiotherapy for pharynx cancer. Acta Oncológica, 2007, 46, 1051-1063.	0.8	12
230	Influence of the linac design on intensity-modulated radiotherapy of head-and-neck plans. Physics in Medicine and Biology, 2007, 52, 169-182.	1.6	15
231	Consequences of leaf calibration errors on IMRT delivery. Physics in Medicine and Biology, 2007, 52, 1147-1156.	1.6	22
232	Intensityâ€Modulated Radiation Therapy for Head and Neck Carcinoma. Oncologist, 2007, 12, 555-564.	1.9	106
233	Function and organ preservation in adult cancers of the head and neck. Expert Review of Anticancer Therapy, 2007, 7, 361-371.	1.1	11
234	Selfâ€consistent tumor control probability and normal tissue complication probability models based	1.6	11
235	Prospective Randomized Study of Intensity-Modulated Radiotherapy on Salivary Gland Function in Early-Stage Nasopharyngeal Carcinoma Patients. Journal of Clinical Oncology, 2007, 25, 4873-4879.	0.8	668
236	Prevalence of Sjogren syndrome among Nagasaki atomic bomb survivors. Annals of the Rheumatic Diseases, 2007, 67, 689-695.	0.5	9
237	Simplifying intensityâ€modulated radiotherapy plans with fewer beam angles for the treatment of oropharyngeal carcinoma. Journal of Applied Clinical Medical Physics, 2007, 8, 26-36.	0.8	7
238	Nasopharyngeal and Oropharyngeal Carcinomas: Target Delineation, Therapy Delivery and Stereotactic Boost Procedures with Intensity-Modulated/Image-Guided Radiation Therapy., 2007, 40, 208-231.		8
239	Outcomes After Extrapleural Pneumonectomy and Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma. Annals of Thoracic Surgery, 2007, 84, 1685-1693.	0.7	216
240	Unilateral versus bilateral irradiation in squamous cell head and neck cancer in relation to patient-rated xerostomia and sticky saliva. Radiotherapy and Oncology, 2007, 85, 83-89.	0.3	59
241	Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2007, 85, 156-170.	0.3	152
242	Sparing the parotid glands and surgically transferred submandibular gland with helical tomotherapy in post-operative radiation of head and neck cancer: A planning study. Radiotherapy and Oncology, 2007, 85, 98-104.	0.3	28
243	Intensity-modulated radiation therapy in head and neck cancer: Prescribed dose, clinical challenges and results. Radiotherapy and Oncology, 2007, 85, 392-398.	0.3	16
244	Progress in radiotherapy technology for non-radiation oncologists. European Journal of Cancer, Supplement, 2007, 5, 402-403.	2.2	0
245	Amifostine: The First Selectiveâ€Target and Broadâ€Spectrum Radioprotector. Oncologist, 2007, 12, 738-747.	1.9	382
246	Solitary Extramedullary Plasmacytoma in the Oropharynx: Advantages of Intensity-Modulated Radiation Therapy. Clinical Lymphoma and Myeloma, 2007, 7, 434-437.	1.4	6

#	Article	IF	CITATIONS
247	The Impact of Metal Artifacts on IMRT Dose Distributions in TCP and NTCP., 2007, , 1750-1753.		O
248	Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head and Neck, 2007, 29, 211-220.	0.9	80
249	Radiotherapy to the salivary glands as treatment of sialorrhea in patients with parkinsonism. Movement Disorders, 2007, 22, 2430-2435.	2.2	50
250	Target Volume Definition for Head and Neck Intensity Modulated Radiotherapy: Pre-clinical Evaluation of PARSPORT Trial Guidelines. Clinical Oncology, 2007, 19, 604-613.	0.6	32
251	The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. International Journal of Radiation Oncology Biology Physics, 2007, 67, 660-669.	0.4	189
252	Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: Comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. International Journal of Radiation Oncology Biology Physics. 2007, 67, 651-659.	0.4	72
253	Impact of Intensity-Modulated Radiotherapy on Health-Related Quality of Life for Head and Neck Cancer Patients: Matched-Pair Comparison with Conventional Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1309-1317.	0.4	114
254	Quantification of Trade-Off Between Parotid Gland Sparing and Planning Target Volume Underdosages in Clinically Node-Negative Head-and-Neck Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 136-143.	0.4	12
255	Cevimeline for the Treatment of Postirradiation Xerostomia in Patients With Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1102-1109.	0.4	87
256	Radiation Doses to Structures Within and Adjacent to the Larynx are Correlated With Long-Term Dietand Speech-Related Quality of Life. International Journal of Radiation Oncology Biology Physics, 2007, 68, 750-757.	0.4	141
257	Dose-Dependent Pulmonary Toxicity After Postoperative Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 350-357.	0.4	152
258	Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Laryngeal and Hypopharyngeal Cancers. International Journal of Radiation Oncology Biology Physics, 2007, 69, 459-468.	0.4	126
259	Health-Related Quality-of-Life Outcomes Following IMRT Versus Conventional Radiotherapy for Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1354-1360.	0.4	52
260	Challenges in the Clinical Application of Advanced Technologies toÂReduce Radiation-Associated Normal Tissue Injury. International Journal of Radiation Oncology Biology Physics, 2007, 69, 4-12.	0.4	35
261	Parotid Gland Dose in Intensity-Modulated Radiotherapy for Head and Neck Cancer: Is What You Plan What You Get?. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1290-1296.	0.4	130
262	In Reply to Dr. Messerschmidt and Dr. Oleka. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1652.	0.4	O
263	In Regard to Mýnter etÂal. Changes in Salivary Gland Function After Radiotherapy of Head and Neck Tumors Measured by Quantitative Pertechnetate Scintigraphy: Comparison of Intensity-Modulated Radiotherapy and Conventional Radiation Therapy With and Without Amifostine. (Int J Radiat Oncol) Tj ETQq0 0	OngBT/O	verdock 10 Tf
264	1651-1652. A Treatment Planning Analysis of Inverse-Planned and Forward-Planned Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1625-1633.	0.4	12

#	Article	IF	CITATIONS
265	Intensity Modulated Radiotherapy Improves Target Coverage and Parotid Gland Sparing When Delivering Total Mucosal Irradiation in Patients With Squamous Cell Carcinoma of Head and Neck of Unknown Primary Site. Medical Dosimetry, 2007, 32, 188-195.	0.4	24
266	Dosimetric Comparison Between 2-Dimensional Radiation Therapy and Intensity Modulated Radiation Therapy in Treatment of Advanced T-Stage Nasopharyngeal Carcinoma: To Treat Less or More in the Planning Organ-At-Risk Volume of the Brainstem and Spinal Cord. Medical Dosimetry, 2007, 32, 263-270.	0.4	51
267	Quantification of Dosimetric Impact of Implementation of On-Board Imaging (OBI) for IMRT Treatment of Head-And-Neck Malignancies. Medical Dosimetry, 2007, 32, 287-294.	0.4	12
268	Physical Models and Simpler Dosimetric Descriptors of Radiation Late Toxicity. Seminars in Radiation Oncology, 2007, 17, 108-120.	1.0	52
269	Normal Tissue Tolerance Dose Metrics for Radiation Therapy of Major Organs. Seminars in Radiation Oncology, 2007, 17, 131-140.	1.0	154
270	Simultaneous Integrated Boost (SIB) for Nasopharynx Cancer with Helical Tomotherapy. Strahlentherapie Und Onkologie, 2007, 183, 497-505.	1.0	62
271	The current status of the delineation and determination of the targets and the radiation protocols for nasopharyngeal cancer with intensity-modulated radiotherapy. Chinese Journal of Clinical Oncology, 2007, 4, 360-366.	0.0	0
272	On the radiobiological impact of metal artifacts in head-and-neck IMRT in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP). Medical and Biological Engineering and Computing, 2007, 45, 1045-1051.	1.6	20
273	A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Physica Medica, 2007, 23, 115-125.	0.4	249
274	Intensity modulation with respiratory gating for radiotherapy of the pleural space. Medical Dosimetry, 2007, 32, 16-22.	0.4	13
275	99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 509-518.	3.3	65
276	Longitudinal Assessment of Parotid Function in Patients Receiving Tomotherapy for Head-and-Neck Cancer. Strahlentherapie Und Onkologie, 2008, 184, 400-405.	1.0	33
277	Clinical application of intensity-modulated radiotherapy for head and neck cancer. Clinical and Translational Oncology, 2008, 10, 407-414.	1.2	3
278	Treatment results and prognostic analysis of 1093 primary nasopharyngeal carcinoma: the experience of a single institution of Guangzhou in the beginning of the 21st century. Chinese-German Journal of Clinical Oncology, 2008, 7, 187-195.	0.1	8
279	IMRT using simultaneous integrated boost (66 Gy in 6 weeks) with and without concurrent chemotherapy in head and neck cancer – toxicity evaluation. Reports of Practical Oncology and Radiotherapy, 2008, 13, 86-95.	0.3	5
280	Intensityâ€modulated radiation therapy. Journal of Surgical Oncology, 2008, 97, 691-696.	0.8	31
281	Intensityâ€modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma. Cancer, 2008, 113, 497-507.	2.0	130
282	SMART (Simultaneous Modulated Accelerated RadioTherapy) for locally advanced nasopharyngeal carcinomas. Head and Neck, 2008, 30, 159-169.	0.9	22

#	Article	IF	CITATIONS
283	Concurrent platinumâ€based chemotherapy and simultaneous modulated accelerated radiation therapy for locally advanced squamous cell carcinoma of the tongue base. Head and Neck, 2008, 30, 327-335.	0.9	42
284	Linac-based on-board imaging feasibility and the dosimetric consequences of head roll in head-and-neck IMRT plans. Medical Dosimetry, 2008, 33, 93-99.	0.4	43
285	A Split-organ Delineation Approach for Dose Optimisation for Intensity-modulated Radiotherapy for Advanced T-stage Nasopharyngeal Carcinoma. Clinical Oncology, 2008, 20, 134-141.	0.6	12
286	Protection of Salivary Function by Concomitant Pilocarpine During Radiotherapy: A Double-Blind, Randomized, Placebo-Controlled Study. International Journal of Radiation Oncology Biology Physics, 2008, 70, 14-22.	0.4	88
287	Intensity-Modulated Radiotherapy for Head and Neck Cancer of Unknown Primary: Toxicity and Preliminary Efficacy. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1100-1107.	0.4	72
288	Helical Tomotherapy for Parotid Gland Tumors. International Journal of Radiation Oncology Biology Physics, 2008, 70, 883-891.	0.4	12
289	Local Anatomic Changes in Parotid and Submandibular Glands During Radiotherapy for Oropharynx Cancer and Correlation With Dose, Studied in Detail With Nonrigid Registration. International Journal of Radiation Oncology Biology Physics, 2008, 70, 875-882.	0.4	118
290	Diffusion-Weighted Magnetic Resonance Imaging to Evaluate Major Salivary Gland Function Before and After Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1365-1371.	0.4	80
291	Dose-Effect Relationships for the Submandibular Salivary Glands and Implications for Their Sparing by Intensity Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 72, 373-382.	0.4	212
292	Beam Path Toxicities to Non-Target Structures During Intensity-Modulated Radiation Therapy for Head and Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 747-755.	0.4	168
293	Large Cohort Dose–Volume Response Analysis of Parotid Gland Function After Radiotherapy: Intensity-Modulated Versus Conventional Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1101-1109.	0.4	54
294	Assessment of Parotid Gland Dose Changes During Head and Neck Cancer Radiotherapy Using Daily Megavoltage Computed Tomography and Deformable Image Registration. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1563-1571.	0.4	180
295	Intensity-Modulated Proton Therapy Versus Helical Tomotherapy in Nasopharynx Cancer: Planning Comparison and NTCP Evaluation. International Journal of Radiation Oncology Biology Physics, 2008, 72, 589-596.	0.4	136
296	Generalized monotonic functional mixed models with application to modelling normal tissue complications. Journal of the Royal Statistical Society Series C: Applied Statistics, 2008, 57, 149-163.	0.5	6
297	A new formula for normal tissue complication probability (NTCP) as a function of equivalent uniform dose (EUD). Physics in Medicine and Biology, 2008, 53, 23-36.	1.6	109
298	Planning and delivery of intensityâ€modulated radiation therapy. Medical Physics, 2008, 35, 5233-5241.	1.6	55
299	The effect of hyperbaric oxygen therapy on quality of life in oral and oropharyngeal cancer patients treated with radiotherapy. International Journal of Oral and Maxillofacial Surgery, 2008, 37, 255-259.	0.7	52
300	Frequency of esophageal stenosis after simultaneous modulated accelerated radiation therapy and chemotherapy for head and neck cancer. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2008, 29, 13-19.	0.6	67

#	Article	IF	CITATIONS
301	The current status of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma. Cancer Treatment Reviews, 2008, 34, 27-36.	3.4	42
302	Positron Emission Tomography/Computed Tomography for Target Delineation in Head and Neck Cancers. Seminars in Nuclear Medicine, 2008, 38, 141-148.	2.5	51
303	Factors associated with radiation-induced nausea and vomiting in head and neck cancer patients treated with intensity modulated radiation therapy. Radiotherapy and Oncology, 2008, 87, 188-194.	0.3	30
304	Clinical implications of the anisotropic analytical algorithm for IMRT treatment planning and verification. Radiotherapy and Oncology, 2008, 86, 276-284.	0.3	70
305	Scintigraphy in prediction of the salivary gland function after gland-sparing intensity modulated radiation therapy for head and neck cancer. Radiotherapy and Oncology, 2008, 87, 260-267.	0.3	40
306	The Role of Radiation Therapy in the Management of Thyroid Cancer. Surgical Oncology Clinics of North America, 2008, 17, 219-232.	0.6	11
307	Rehabilitation of Dysphagia Following Head and Neck Cancer. Physical Medicine and Rehabilitation Clinics of North America, 2008, 19, 889-928.	0.7	155
308	Lyman–Kutcher–Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. Physics in Medicine and Biology, 2008, 53, 737-755.	1.6	117
309	Impact of Late Treatment-Related Toxicity on Quality of Life Among Patients With Head and Neck Cancer Treated With Radiotherapy. Journal of Clinical Oncology, 2008, 26, 3770-3776.	0.8	569
310	Advances in radiation therapy of head and neck cancer. Expert Review of Anticancer Therapy, 2008, 8, 633-644.	1.1	16
311	Image-Based Modeling of Normal Tissue Complication Probability for Radiation Therapy. Cancer Treatment and Research, 2008, , 211-252.	0.2	13
312	Superiority of intensity-modulated radiotherapy over three-dimensional conformal radiotherapy combined with brachytherapy in nasopharyngeal carcinoma: a planning study. British Journal of Radiology, 2008, 81, 397-405.	1.0	16
313	Role of the parameters involved in the plan optimization based on the generalized equivalent uniform dose and radiobiological implications. Physics in Medicine and Biology, 2008, 53, 1665-1675.	1.6	13
314	Volumetric image-guidance: Does routine usage prompt adaptive re-planning? An institutional review. Acta Oncol $ ilde{A}^3$ gica, 2008, 47, 1444-1453.	0.8	31
315	Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Physics in Medicine and Biology, 2008, 53, 4153-4167.	1.6	69
316	Is daily computed tomography image guidance necessary for nasal cavity and nasopharyngeal radiotherapy? An investigation based on helical tomotherapy. Journal of Applied Clinical Medical Physics, 2008, 9, 36-46.	0.8	20
317	Complications of Radiation Therapy. , 2009, , 167-179.		0
318	Radiation-Induced Xerostomia: Objective Evaluation of Salivary Gland Injury Using MR Sialography. American Journal of Neuroradiology, 2009, 30, 53-58.	1.2	41

#	Article	IF	CITATIONS
319	IMRT reduces xerostomia and potentially improves QoL. Nature Reviews Clinical Oncology, 2009, 6, 567-568.	12.5	42
320	Improved critical structure sparing with biologically based IMRT optimization. Medical Physics, 2009, 36, 1790-1799.	1.6	46
321	Comparison of IMRT planning with two-step and one-step optimization: a strategy for improving therapeutic gain and reducing the integral dose. Physics in Medicine and Biology, 2009, 54, 7183-7198.	1.6	9
322	The feasibility of using Pareto fronts for comparison of treatment planning systems and delivery techniques. Acta Oncológica, 2009, 48, 233-237.	0.8	43
323	Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. British Journal of Radiology, 2009, 82, 585-594.	1.0	43
324	Unknown primary head and neck cancer treated with intensity-modulated radiation therapy: To what extent the volume should be irradiated. Oral Oncology, 2009, 45, 474-479.	0.8	27
325	A survey of techniques to reduce and manage external beam radiation-induced xerostomia in British oncology and radiotherapy departments. Radiography, 2009, 15, 283-291.	1.1	4
326	Accelerated fractionation head and neck intensityâ€modulated radiation therapy and concurrent chemotherapy in the community setting: Safety and efficacy considerations. Head and Neck, 2009, 31, 1144-1151.	0.9	5
327	New insights in the vascular supply of the human parotid glandâ€"Consequences for parotid glandâ€sparing irradiation. Head and Neck, 2010, 32, 837-843.	0.9	10
328	Radiationâ€induced volume changes in parotid and submandibular glands in patients with head and neck cancer receiving postoperative radiotherapy: A longitudinal study. Laryngoscope, 2009, 119, 1966-1974.	1.1	64
329	Diagnosis and treatment of xerostomia (dry mouth). Odontology / the Society of the Nippon Dental University, 2009, 97, 76-83.	0.9	136
330	Reducing the Risk of Xerostomia and Mandibular Osteoradionecrosis: The Potential Benefits of Intensity Modulated Radiotherapy in Advanced Oral Cavity Carcinoma. Medical Dosimetry, 2009, 34, 217-224.	0.4	51
331	Obtaining Normal Tissue Constraints Using Intensity Modulated Radiotherapy (IMRT) in Patients with Oral Cavity, Oropharnygeal, and Laryngeal Carcinoma. Medical Dosimetry, 2009, 34, 279-284.	0.4	3
332	Radiation-Induced Salivary Gland Dysfunction Results From p53-Dependent Apoptosis. International Journal of Radiation Oncology Biology Physics, 2009, 73, 523-529.	0.4	107
333	Impact of Residual Setup Error on Parotid Gland Dose in Intensity-Modulated Radiation herapy with or without Planning Organ-at-Risk Margin. Strahlentherapie Und Onkologie, 2009, 185, 453-459.	1.0	17
334	Modeling of Salivary Production Recovery After Radiotherapy Using Mixed Models: Determination of Optimal Dose Constraint for IMRT Planning and Construction of Convenient Tools to Predict Salivary Function. International Journal of Radiation Oncology Biology Physics, 2009, 73, 178-186.	0.4	34
335	An Interlaced IMRT Technique for Elongated Tumor Volumes. Medical Dosimetry, 2009, 34, 170-178.	0.4	2
336	Radiation-induced Xerostomia: Pathophysiology, Prevention and Treatment. Clinical Oncology, 2009, 21, 737-744.	0.6	42

#	Article	IF	Citations
337	A Dosimetric Comparison of Proton and Intensity-Modulated Photon Radiotherapy for Pediatric Parameningeal Rhabdomyosarcomas. International Journal of Radiation Oncology Biology Physics, 2009, 74, 179-186.	0.4	96
338	Intensity-Modulated Radiotherapy Reduces Radiation-Induced Morbidity and Improves Health-Related Quality of Life: Results of a Nonrandomized Prospective Study Using a Standardized Follow-Up Program. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1-8.	0.4	280
339	Lacrimal Gland Radiosensitivity in Uveal Melanoma Patients. International Journal of Radiation Oncology Biology Physics, 2009, 74, 497-502.	0.4	20
340	A Prospective Study of Salivary Gland Function in Lymphoma Patients Receiving Head and Neck Irradiation. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1079-1083.	0.4	21
341	Modeling Plan-Related Clinical Complications Using Machine Learning Tools in a Multiplan IMRT Framework. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1617-1626.	0.4	29
342	Bath and Shower Effects in the Rat Parotid Gland Explain Increased Relative Risk of Parotid Gland Dysfunction After Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1002-1005.	0.4	59
343	Adaptive Replanning Strategies Accounting for Shrinkage in Head and Neck IMRT. International Journal of Radiation Oncology Biology Physics, 2009, 75, 924-932.	0.4	215
344	Analysis of Salivary Flow and Dose–Volume Modeling of Complication Incidence in Patients With Head-and-Neck Cancer Receiving Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1252-1259.	0.4	36
345	Sensitivity of Salivary Glands to Radiation: from Animal Models to Therapies. Journal of Dental Research, 2009, 88, 894-903.	2.5	203
346	Radiation Therapy for Head and Neck Cancers. Seminars in Oncology Nursing, 2009, 25, 193-202.	0.7	20
348	Accuracy requirements for head and neck intensity-modulated radiation therapy based on observed dose response of the major salivary glands. Radiotherapy and Oncology, 2009, 93, 109-114.	0.3	11
349	Delineation guidelines for organs at risk involved in radiation-induced salivary dysfunction and xerostomia. Radiotherapy and Oncology, 2009, 93, 545-552.	0.3	101
350	Evaluation of the impact of dental artefacts on intensity-modulated radiotherapy planning for the head and neck. Radiotherapy and Oncology, 2009, 93, 553-558.	0.3	14
351	¹⁸ F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy. Journal of Nuclear Medicine, 2009, 50, 1655-1665.	2.8	129
352	EVALUATION OF GANTRY ANGLE OPTIMIZATION FOR IMRT TREATMENT PLANNING SYSTEMS USING THE PARETO FRONT APPRO1ACH. Radiotherapy and Oncology, 2009, 92, S87.	0.3	0
353	Machine Learning for Modeling Dose-Related Organ-at-Risk Complications after Radiation Therapy. , 2009, , .		1
354	Effect of Sameâ€dose Single or Dual Field Irradiation on Damage to Miniature Pig Parotid Glands. International Journal of Oral Science, 2009, 1, 16-25.	3.6	5
355	Xerostomia in Long-term Survivors of Aggressive Non-Hodgkin's Lymphoma of Waldeyer's Ring. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 145-149.	0.6	12

#	Article	IF	CITATIONS
356	Proton Therapy for Maxillary Sinus Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 296-303.	0.6	39
357	Patterns of Local and Nodal Failure in Malignant Pleural Mesothelioma After Extrapleural Pneumonectomy and Photon-Electron Radiotherapy. Journal of Thoracic Oncology, 2009, 4, 746-750.	0.5	44
358	The volume effect in radiotherapy. , 2009, , 191-206.		11
359	Machine Learning for the Prediction of Organ Damage from Cancer Radiotherapy. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2009, 42, 1523-1528.	0.4	0
360	IGF1 activates cell cycle arrest following irradiation by reducing binding of î"Np63 to the p21 promoter. Cell Death and Disease, 2010, 1, e50-e50.	2.7	38
361	Supportive care in head and neck oncology. Current Opinion in Oncology, 2010, 22, 221-225.	1.1	20
362	Report 83. Journal of the ICRU, 2010, 10, NP.1-NP.	6.0	73
363	A Comparison of Dose–Response Models for the Parotid Gland in a Large Group of Head-and-Neck Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1259-1265.	0.4	77
365	Simultaneous Integrated Boost Intensityâ€'Modulated Radiotherapy (SIBâ€'IMRT) in Nasopharyngeal Cancer. Strahlentherapie Und Onkologie, 2010, 186, 135-142.	1.0	23
366	Investigations on Parotid Gland Recovery after IMRT in Head and Neck Tumor Patients. Strahlentherapie Und Onkologie, 2010, 186, 665-671.	1.0	26
367	A Novel Dose Constraint to Reduce Xerostomia in Head-and-Neck Cancer Patients Treated With Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 77, 269-276.	0.4	30
368	Ipsilateral Irradiation for Oral and Oropharyngeal Carcinoma Treated With Primary Surgery and Postoperative Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 682-688.	0.4	47
369	Comparative Analysis of an Image-Guided Versus a Nonâ€"Image-Guided Setup Approach in Terms of Delivered Dose to the Parotid Glands in Head-and-Neck Cancer IMRT. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1266-1273.	0.4	33
370	SORS: A New Software for the Simulation of Radiotherapy Schedule. Medical Dosimetry, 2010, 35, 208-213.	0.4	1
371	Dysphagia in Head and Neck Cancer Patients Treated with Chemoradiotherapy. Dysphagia, 2010, 25, 139-152.	1.0	93
372	A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Supportive Care in Cancer, 2010, 18, 1039-1060.	1.0	338
373	A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact. Supportive Care in Cancer, 2010, 18, 1061-1079.	1.0	219
375	Adaptive Radiotherapy of Head and Neck Cancer. Seminars in Radiation Oncology, 2010, 20, 84-93.	1.0	164

#	Article	IF	CITATIONS
376	Intensityâ€modulated radiotherapy outcomes for oropharyngeal squamous cell carcinoma patients stratified by p16 status. Cancer, 2010, 116, 2645-2654.	2.0	42
377	Evaluation of trends in the use of intensityâ€modulated radiotherapy for head and neck cancer from 2000 through 2005. Cancer, 2010, 116, 3505-3512.	2.0	57
378	Radiation-Induced Damage to Microstructure of Parotid Gland: Evaluation Using High-Resolution Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1030-1038.	0.4	18
379	Radiotherapy Dose–Volume Effects on Salivary Gland Function. International Journal of Radiation Oncology Biology Physics, 2010, 76, S58-S63.	0.4	462
380	Parotid Gland Function After Radiotherapy: The Combined Michigan and Utrecht Experience. International Journal of Radiation Oncology Biology Physics, 2010, 78, 449-453.	0.4	155
381	The Lessons of QUANTEC: Recommendations for Reporting and Gathering Data on Dose–Volume Dependencies of Treatment Outcome. International Journal of Radiation Oncology Biology Physics, 2010, 76, S155-S160.	0.4	171
382	Emphasizing Conformal Avoidance Versus Target Definition for IMRT Planning in Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 950-958.	0.4	78
383	Insulin-Like Growth Factor–1 Preserves Salivary Gland Function After Fractionated Radiation. International Journal of Radiation Oncology Biology Physics, 2010, 78, 579-586.	0.4	38
384	Clinical Management of Salivary Gland Hypofunction and Xerostomia in Head-and-Neck Cancer Patients: Successes and Barriers. International Journal of Radiation Oncology Biology Physics, 2010, 78, 983-991.	0.4	278
385	Radiobiological evaluation of forward and inverse IMRT using different fractionations for head and neck tumours. Radiation Oncology, 2010, 5, 57.	1.2	17
386	Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients. Radiation Oncology, 2010, 5, 93.	1.2	35
387	Intensity modulated radiotherapy (IMRT) in the management of locally advanced oropharyngeal squamous cell carcinomata (SCC): disease control and functional outcome using the therapy outcome measure (TOM) score - report from a single U.K. institution. Head & Neck Oncology, 2010, 2, 28.	2.3	9
389	Nasopharyngeal Cancer. Medical Radiology, 2010, , .	0.0	11
390	Radiation-induced Parotid Gland Changes in Oral Cancer Patients: Correlation Between Parotid Volume and Saliva Production. Japanese Journal of Clinical Oncology, 2010, 40, 42-46.	0.6	45
391	The role of intensity-modulated radiotherapy in head and neck cancer. Indian Journal of Cancer, 2010, 47, 267.	0.2	26
392	Clinical and dosimetric factors associated with a prolonged feeding tube requirement in patients treated with chemoradiotherapy (CRT) for head and neck cancers. Annals of Oncology, 2010, 21, 145-151.	0.6	25
393	Diagnosis and Treatment of a Neck Node Swelling Suspicious for a Malignancy: An Algorithmic Approach. International Journal of Surgical Oncology, 2010, 2010, 1-8.	0.3	9
394	Radiotherapy for Head and Neck Cancer. Seminars in Plastic Surgery, 2010, 24, 127-136.	0.8	96

#	Article	IF	CITATIONS
395	The minimum knowledge base for predicting organ-at-risk dose–volume levels and plan-related complications in IMRT planning. Physics in Medicine and Biology, 2010, 55, 1935-1947.	1.6	14
396	Quantitative salivary gland scintigraphy in head and neck cancer patients following radiotherapy. Revista Española De Medicina Nuclear, 2010, 29, 165-171.	0.3	O
398	Conservation of salivary function and new external head and neck radiation techniques. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2010, 127, 197-203.	0.4	3
400	The dosimetric consequences of anatomic changes in head and neck radiotherapy patients. Journal of Medical Imaging and Radiation Oncology, 2010, 54, 497-504.	0.9	23
401	Unilateral radiotherapy for tonsil cancer: Potential dose distribution optimization with a simple two-field intensity-modulated radiation therapy beam arrangement. Radiotherapy and Oncology, 2010, 94, 334-338.	0.3	1
402	A two-variable linear model of parotid shrinkage during IMRT for head and neck cancer. Radiotherapy and Oncology, 2010, 94, 206-212.	0.3	43
403	Evaluation of the radiobiological impact of anatomic modifications during radiation therapy for head and neck cancer: Can we simply summate the dose?. Radiotherapy and Oncology, 2010, 96, 131-138.	0.3	15
404	Evidence-based review: Quality of life following head and neck intensity-modulated radiotherapy. Radiotherapy and Oncology, 2010, 97, 249-257.	0.3	47
405	Evidence-based organ-sparing radiotherapy in head and neck cancer. Lancet Oncology, The, 2010, 11, 85-91.	5.1	139
406	Parotid gland function after radiotherapy. Lancet Oncology, The, 2010, 11, 412.	5.1	7
407	Imaging of normal lung, liver and parotid gland function for radiotherapy. Acta Oncol \tilde{A}^3 gica, 2010, 49, 997-1011.	0.8	28
408	Do we need fractionation-corrected doses in sequential two-phase treatments? A quantification of dose differences between non-corrected and corrected combined non-uniform dose distributions in normal tissue. Acta Oncológica, 2010, 49, 1253-1260.	0.8	4
409	Patterns of relapse following surgery and postoperative intensity modulated radiotherapy for oral and oropharyngeal cancer. Acta Oncol \tilde{A}^3 gica, 2011, 50, 1119-1125.	0.8	20
410	The Effect of Hyperbaric Oxygenation on Postradiation Xerostomia and Saliva in Patients with Head and Neck Tumours. Caries Research, 2011, 45, 136-141.	0.9	23
411	Commentary: How radiation damages teeth: Getting to the root of the problem. Practical Radiation Oncology, 2011, 1, 149-151.	1.1	1
412	IsoBED: a tool for automatic calculation of biologically equivalent fractionation schedules in radiotherapy using IMRT with a simultaneous integrated boost (SIB) technique. Journal of Experimental and Clinical Cancer Research, 2011, 30, 52.	3.5	19
413	Radiation Injury of the Parotid Glands During Treatment for Head and Neck Cancer: Assessment Using Dynamic Contrast-Enhanced MR Imaging. Radiation Research, 2011, 175, 291-296.	0.7	25
414	Salivary Gland Disorders. Dental Clinics of North America, 2011, 55, 121-140.	0.8	5

#	Article	IF	CITATIONS
415	Systematic review and meta-analysis of radiotherapy in various head and neck cancers: Comparing photons, carbon-ions and protons. Cancer Treatment Reviews, 2011, 37, 185-201.	3.4	86
416	Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: Is there a worthwhile quality of life gain?. Cancer Treatment Reviews, 2011, 37, 511-519.	3.4	90
417	Organ-sparing radiation therapy for head and neck cancer. Nature Reviews Clinical Oncology, 2011, 8, 639-648.	12.5	73
418	Recovery of salivary epidermal growth factor in parotid saliva following parotid sparing radiation therapy: a proof-of-principle study. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2011, 111, 64-70.	1.6	15
420	Sequentially delivered boost plans are superior to simultaneously delivered plans in head and neck cancer when the boost volume is located further away from the parotid glands. Radiotherapy and Oncology, 2011, 98, 51-56.	0.3	11
421	Parotid gland as a risk organ in whole brain radiotherapy. Radiotherapy and Oncology, 2011, 98, 223-226.	0.3	18
422	Dose–volume analysis of locoregional recurrences in head and neck IMRT, as determined by deformable registration: A prospective multi-institutional trial. Radiotherapy and Oncology, 2011, 99, 101-107.	0.3	29
423	Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: Is the gain in dose distribution worth the effort?. Radiotherapy and Oncology, 2011, 101, 343-350.	0.3	79
424	Evaluation of the Planning Target Volume in the Treatment of Head and Neck Cancer With Intensity-Modulated Radiotherapy: What Is the Appropriate Expansion Margin in the Setting of Daily Image Guidance?. International Journal of Radiation Oncology Biology Physics, 2011, 81, 943-949.	0.4	79
425	Impact of Salivary Gland Dosimetry on Post-IMRT Recovery of Saliva Output and Xerostomia Grade for Head-and-Neck Cancer Patients Treated With or Without Contralateral Submandibular Gland Sparing: A Longitudinal Study. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1479-1487.	0.4	60
426	Chemo-IMRT of Oropharyngeal Cancer Aiming to Reduce Dysphagia: Swallowing Organs Late Complication Probabilities and Dosimetric Correlates. International Journal of Radiation Oncology Biology Physics, 2011, 81, e93-e99.	0.4	216
427	Outcomes of Patients With Head-and-Neck Cancer of Unknown Primary Origin Treated With Intensity-Modulated Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e83-e91.	0.4	38
428	Xerostomia. , 2011, , 232-242.		0
429	42 Influence of (Chemo-)Radiotherapy on Salivary Gland Function and Its Impact on Quality of Life. , 2011, , .		0
430	Adaptive Radiation Therapy for Head and Neck Cancerâ€"Can an Old Goal Evolve into a New Standard?. Journal of Oncology, 2011, 2011, 1-13.	0.6	56
431	Head and Neck Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 596-650.	2.3	213
432	Posttreatment Quality-of-Life Assessment in Patients With Head and Neck Cancer Treated With Intensity-modulated Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 478-482.	0.6	21
433	Oral cancers: supportive care issues. Periodontology 2000, 2011, 57, 118-131.	6.3	9

#	Article	IF	CITATIONS
434	Sonographic Appearance of Parotid Glands in Patients Treated With Intensity-Modulated Radiotherapy or Conventional Radiotherapy for Nasopharyngeal Carcinoma. Ultrasound in Medicine and Biology, 2011, 37, 220-230.	0.7	12
435	Investigation of Pitch and Jaw Width to Decrease Delivery Time of Helical Tomotherapy Treatments for Head and Neck Cancer. Medical Dosimetry, 2011, 36, 397-403.	0.4	12
436	Salivary gland sparing in the treatment of head and neck cancer. Expert Review of Anticancer Therapy, 2011, 11, 1437-1448.	1.1	8
437	Volumetric modulated arc therapy: a review of current literature and clinical use in practice. British Journal of Radiology, 2011, 84, 967-996.	1.0	503
438	Dysphagia. Strahlentherapie Und Onkologie, 2011, 187, 744-749.	1.0	65
439	Application of Constant vs. Variable Relative Biological Effectiveness in Treatment Planning of Intensity-Modulated Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2011, 79, 80-88.	0.4	81
440	Preliminary comp arison of helical tomotherapy and mixed beams of unmodulated electrons and intensity modulated radiation therapy for treating superficial cancers of the parotid gland and nasal cavity. Radiation Oncology, 2011, 6, 178.	1.2	7
441	The protective efficacy of basic fibroblast growth factor in radiation-induced salivary gland dysfunction in mice. Laryngoscope, 2011, 121, 1870-1875.	1.1	33
442	Regeneration of radiation damaged salivary glands with adipose-derived stromal cells. Laryngoscope, 2011, 121, 1864-1869.	1.1	82
443	Intensityâ€modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx. Head and Neck, 2011, 33, 103-111.	0.9	30
444	Intensity-Modulated Radiation Therapy Significantly Improves Acute Gastrointestinal Toxicity in Pancreatic and Ampullary Cancers. International Journal of Radiation Oncology Biology Physics, 2011, 79, 158-162.	0.4	135
445	Development and Validation of a Heart Atlas to Study Cardiac Exposure to Radiation Following Treatment for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 10-18.	0.4	566
446	Improved Dosimetric and Clinical Outcomes With Intensity-Modulated Radiotherapy for Head-and-Neck Cancer of Unknown Primary Origin. International Journal of Radiation Oncology Biology Physics, 2011, 79, 756-762.	0.4	48
447	Phase II Trial of Hyperfractionated Intensity-Modulated Radiation Therapy and Concurrent Weekly Cisplatin for Stage III and IVa Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1081-1088.	0.4	36
448	Tumour Shrinkage and Contour Change during Radiotherapy Increase the Dose to Organs at Risk but not the Target Volumes for Head and Neck Cancer Patients Treated on the TomoTherapy HiArtâ,,¢ System. Clinical Oncology, 2011, 23, 40-47.	0.6	40
449	Quantitative estimation of doses to salivary glands from using brachytherapy in head and neck cancers. Brachytherapy, 2011, 10, 81-86.	0.2	5
450	The Potential Benefit of Radiotherapy with Protons in Head and Neck Cancer with Respect to Normal Tissue Sparing: A Systematic Review of Literature. Oncologist, 2011, 16, 366-377.	1.9	127
451	Comparison of IMRT Techniques in the Radiotherapeutic Management of Head and Neck Cancer: Is Tomotherapy "Better―than Step-and-Shoot IMRT?. Technology in Cancer Research and Treatment, 2011, 10, 171-177.	0.8	15

#	Article	IF	CITATIONS
452	Longitudinal Changes over 2 Years in Parotid Glands of Patients Treated with Preoperative 30-Gy Irradiation for Oral Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 503-507.	0.6	12
453	Assessment of post-radiotherapy salivary glands. British Journal of Radiology, 2011, 84, 393-402.	1.0	96
454	Intensity-modulated radiotherapy in patients with head and neck cancer: a European single-centre experience. British Journal of Radiology, 2011, 84, 367-374.	1.0	24
455	Submandibular gland-sparing intensity modulated radiotherapy in the treatment of head and neck cancer: Sites of locoregional relapse and survival. Acta OncolA ³ gica, 2012, 51, 735-742.	0.8	21
456	Interobserver variation in parotid gland delineation: a study of its impact on intensity-modulated radiotherapy solutions with a systematic review of the literature. British Journal of Radiology, 2012, 85, 1070-1077.	1.0	32
457	Introducing multiple treatment plan-based comparison to investigate the performance of gantry angle optimisation (GAO) in IMRT for head and neck cancer. Acta Oncológica, 2012, 51, 743-751.	0.8	5
458	Clinical evaluation of intensity-modulated radiotherapy for head and neck cancers. British Journal of Radiology, 2012, 85, 487-494.	1.0	61
459	Is There a Clinical Benefit to Adaptive Planning During Tomotherapy in Patients with Head and Neck Cancer at Risk for Xerostomia?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 261-266.	0.6	27
460	Intensity-modulated radiotherapy for nasopharyngeal carcinoma: improvement of the therapeutic ratio with helical tomotherapy <i>vs</i> segmental multileaf collimator-based techniques. British Journal of Radiology, 2012, 85, e537-e543.	1.0	23
461	Correlation of Parotid Gland Function in Head and Neck Cancer Patients treated with Intensity-modulated Radiotherapy. International Journal of Head and Neck Surgery, 2012, 3, 1-4.	0.1	1
462	Intensity-Modulated Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer: Toxicities and Efficacy. Oncologist, 2012, 17, 673-681.	1.9	19
464	A dosimetric comparative study between conformal and intensity modulated radiation therapy in the treatment of primary nasopharyngeal carcinomas: the Egyptian experience. Chinese-German Journal of Clinical Oncology, 2012, 11, 626-631.	0.1	2
465	FDG-PET Assessment of the Effect of Head and Neck Radiotherapy on Parotid Gland Glucose Metabolism. International Journal of Radiation Oncology Biology Physics, 2012, 82, 321-326.	0.4	36
466	Normal Tissue Complication Probability Estimation by the Lyman-Kutcher-Burman Method Does Not Accurately Predict Spinal Cord Tolerance to Stereotactic Radiosurgery. International Journal of Radiation Oncology Biology Physics, 2012, 82, 2025-2032.	0.4	28
467	Dentalmaps: Automatic Dental Delineation for Radiotherapy Planning in Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1858-1865.	0.4	23
468	Treatment Planning Constraints to Avoid Xerostomia in Head-and-Neck Radiotherapy: An Independent Test of QUANTEC Criteria Using a Prospectively Collected Dataset. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1108-1114.	0.4	55
469	Dosimetric Predictors of Radiation-induced Acute Nausea and Vomiting in IMRT for Nasopharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, 176-182.	0.4	39
470	Can Intensity-Modulated Radiotherapy Preserve Oral Health-Related Quality of Life of Nasopharyngeal Carcinoma Patients?. International Journal of Radiation Oncology Biology Physics, 2012, 83, e213-e221.	0.4	24

#	Article	IF	CITATIONS
471	Intensity-modulated radiotherapy in head and neck cancer: Results of the prospective study GORTEC 2004–03. Radiotherapy and Oncology, 2012, 103, 57-62.	0.3	113
472	Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial. Radiotherapy and Oncology, 2012, 103, 82-87.	0.3	65
474	Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. European Journal of Cancer, 2012, 48, 1692-1699.	1.3	55
475	Feasibility of image-guided radiotherapy based on helical tomotherapy to reduce contralateral parotid dose in head and neck cancer. BMC Cancer, 2012, 12, 175.	1.1	10
476	The Evolving Role of Positron Emission Tomography-Computed Tomography in Organ-Preserving Treatment of Head and Neck Cancer. Seminars in Nuclear Medicine, 2012, 42, 320-327.	2.5	24
478	Current issues in combined modality therapy in locally advanced head and neck cancer. Critical Reviews in Oncology/Hematology, 2012, 84, 261-273.	2.0	20
479	Ultrasound GLCM texture analysis of radiationâ€induced parotidâ€gland injury in headâ€andâ€neck cancer radiotherapy: An <i>in vivo</i> study of late toxicity. Medical Physics, 2012, 39, 5732-5739.	1.6	139
480	Advanced Radiation Therapy for Head and Neck Cancer: A New Standard of Practice. , 2012, , .		1
481	Influence of intensityâ€modulated radiation therapy technique on xerostomia and related quality of life in patients treated with intensityâ€modulated radiation therapy for nasopharyngeal cancer. Head and Neck, 2012, 34, 328-335.	0.9	17
482	Randomized controlled trial of acupuncture for prevention of radiationâ€induced xerostomia among patients with nasopharyngeal carcinoma. Cancer, 2012, 118, 3337-3344.	2.0	84
483	Phase 2 results from Radiation Therapy Oncology Group Study 0537. Cancer, 2012, 118, 4244-4252.	2.0	44
484	Intensity-modulated radiation therapy for nasopharyngeal carcinoma: a review. Journal of Radiation Oncology, 2012, 1, 129-146.	0.7	59
485	Current Progress in Adaptive Radiation Therapy for Head and Neck Cancer. Current Oncology Reports, 2012, 14, 139-147.	1.8	38
486	Adaptive Radiotherapy Using Helical Tomotherapy for Head and Neck Cancer in Definitive and Postoperative Settings: Initial Results. Clinical Oncology, 2012, 24, 208-215.	0.6	71
487	Dosimetric evaluation of a three-phase adaptive radiotherapy for nasopharyngeal carcinoma using helical tomotherapy. Medical Dosimetry, 2012, 37, 92-97.	0.4	20
488	Patterns of Disease Recurrence Following Treatment of Oropharyngeal Cancer With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, 941-947.	0.4	99
489	Xerostomia after radiotherapy. Strahlentherapie Und Onkologie, 2013, 189, 216-222.	1.0	43
490	Three dimensional conformal postoperative radiotherapy for unilateral parotid gland cancer: A comparison of three different parotid gland irradiation techniques. Alexandria Journal of Medicine, 2013, 49, 379-384.	0.4	0

#	Article	IF	CITATIONS
491	Effect of MLC leaf position, collimator rotation angle, and gantry rotation angle errors on intensity-modulated radiotherapy plans for nasopharyngeal carcinoma. Medical Dosimetry, 2013, 38, 143-147.	0.4	21
492	The Preventive and Therapeutic Effect of Acupuncture for Radiation-Induced Xerostomia in Patients With Head and Neck Cancer. Integrative Cancer Therapies, 2013, 12, 197-205.	0.8	43
493	Sonographic appearance of submandibular glands in patients treated with external beam radiotherapy for nasopharyngeal carcinoma. Journal of Clinical Ultrasound, 2013, 41, 472-478.	0.4	2
496	Clinical implications in the use of the PBC algorithm versus the AAA by comparison of different NTCP models/parameters. Radiation Oncology, 2013, 8, 164.	1.2	18
497	Tumori maligni del velo palatino. EMC - Otorinolaringoiatria, 2013, 12, 1-16.	0.0	0
498	The effect of concomitant chemotherapy on parotid gland function following head and neck IMRT. Radiotherapy and Oncology, 2013, 106, 346-351.	0.3	21
499	Dose–response analysis of parotid gland function: What is the best measure of xerostomia?. Radiotherapy and Oncology, 2013, 106, 341-345.	0.3	24
500	Adaptive radiotherapy for head and neck cancer—Dosimetric results from a prospective clinical trial. Radiotherapy and Oncology, 2013, 106, 80-84.	0.3	168
501	An in silico comparison between margin-based and probabilistic target-planning approaches in head and neck cancer patients. Radiotherapy and Oncology, 2013, 109, 430-436.	0.3	14
502	Parotid Glands Dose–Effect Relationships Based on Their Actually Delivered Doses: Implications for Adaptive Replanning in Radiation Therapy of Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 676-682.	0.4	67
504	RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison. Radiation Oncology, 2013, 8, 37.	1.2	45
505	Scintigraphic assessment of salivary function after intensity-modulated radiotherapy for head and neck cancer: Correlations with parotid dose and quality of life. Oral Oncology, 2013, 49, 42-48.	0.8	32
506	Magnetic resonance sialography for investigating major salivary gland duct system after intensity-modulated radiotherapy of nasopharyngeal carcinoma. International Journal of Clinical Oncology, 2013, 18, 801-807.	1.0	10
508	Sicca symptoms and their impact on quality of life among very long-term survivors after hematopoietic SCT. Bone Marrow Transplantation, 2013, 48, 988-993.	1.3	20
509	Superficial Parotid Lobe–Sparing Delineation Approach: A Better Method of Dose Optimization to Protect the Parotid Gland in Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. Current Oncology, 2013, 20, 577-584.	0.9	13
510	A Pragmatic Contouring Guideline for Salivary Gland Structures in Head and Neck Radiation Oncology. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 70-76.	0.6	19
511	Xerostomia in patients treated for oropharyngeal carcinoma: Comparing linear accelerator-based intensity-modulated radiation therapy with helical tomotherapy. Head and Neck, 2013, 36, n/a-n/a.	0.9	4
512	Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER-Medicare analysis. Head and Neck, 2013, 35, 1599-1605.	0.9	52

#	Article	IF	CITATIONS
513	Evaluating the dosimetric effect of treatmentâ€induced changes in virally mediated head and neck cancer patients. Journal of Medical Radiation Sciences, 2013, 60, 139-144.	0.8	0
514	Complications et séquelles de la radiothérapie. , 2013, , 13-65.		1
515	The Rapalogue, CCI-779, Improves Salivary Gland Function following Radiation. PLoS ONE, 2014, 9, e113183.	1.1	28
516	Clinical Outcomes and Prognostic Factors of 695 Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiotherapy. BioMed Research International, 2014, 2014, 1-10.	0.9	49
517	Postradiation xerostomia and oral pain. Journal of the American Dental Association, 2014, 145, 964-965.	0.7	2
518	Xerostomia. Monographs in Oral Science, 2014, 24, 109-125.	0.9	32
519	Effect of fractionated radiotherapy on the parotid gland: an experimental study in Brazilian minipigs. International Archives of Otorhinolaryngology, 2014, 17, 163-167.	0.3	10
520	Ultrasonic Nakagamiâ€parameter characterization of parotidâ€gland injury following headâ€andâ€neck radiotherapy: A feasibility study of late toxicity. Medical Physics, 2014, 41, 022903.	1.6	19
521	Incorporating singleâ€side sparing in models for predicting parotid dose sparing in head and neck IMRT. Medical Physics, 2014, 41, 021728.	1.6	22
522	Indications for the use of external beam radiation in thyroid cancer. Current Opinion in Oncology, 2014, 26, 45-50.	1.1	17
523	Submandibular Gland-sparing Intensity-modulated Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 514-516.	0.6	26
524	Developing an adaptive radiation therapy strategy for nasopharyngeal carcinoma. Journal of Radiation Research, 2014, 55, 293-304.	0.8	35
525	Beam path toxicity in candidate organs-at-risk: Assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy. Radiotherapy and Oncology, 2014, 111, 281-288.	0.3	54
526	The effect of radiotherapy on dental hard tissue—a systematic review. Clinical Oral Investigations, 2014, 18, 17-24.	1.4	107
527	Management of radiotherapy-induced salivary hypofunction and consequent xerostomia in patients with oral or head and neck cancer: meta-analysis and literature review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 117, 595-607.	0.2	48
528	Error in the parotid contour delineated using computed tomography images rather than magnetic resonance images during radiotherapy planning for nasopharyngeal carcinoma. Japanese Journal of Radiology, 2014, 32, 211-216.	1.0	8
529	Changes in parotid gland morphology and function in patients treated with intensity-modulated radiotherapy for nasopharyngeal and oropharyngeal tumors. Oral Radiology, 2014, 30, 135-141.	0.9	8
530	Intensity-modulated radiation therapy for head and neck cancer: Systematic review and meta-analysis. Radiotherapy and Oncology, 2014, 110, 9-15.	0.3	224

#	Article	IF	CITATIONS
531	Mesenchymal stem cell therapy for salivary gland dysfunction andÂxerostomia: a systematic review of preclinical studies. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2014, 117, 335-342.e1.	0.2	47
532	Treatment of Radiation Injury. Advances in Wound Care, 2014, 3, 1-11.	2.6	29
533	Salivary Gland Disorders. Medical Clinics of North America, 2014, 98, 1407-1449.	1.1	33
534	Adjuvant simultaneous integrated boost IMRT for patients with intermediate- and high-risk head and neck cancer: Outcome, toxicities and patterns of failure. Oral Oncology, 2014, 50, 1114-1121.	0.8	6
535	Dosimetric analytic comparison of inverse and forward planned IMRT techniques in the treatment of head and neck cancer. Journal of the Egyptian National Cancer Institute, 2014, 26, 119-125.	0.6	2
536	Patterns-of-failure after helical tomotherapy-based chemoradiotherapy for head and neck cancer: Implications for CTV margin, elective nodal dose and bilateral parotid sparing. Oral Oncology, 2014, 50, 520-526.	0.8	25
537	Radiotherapy induced xerostomia: Mechanisms, diagnostics, prevention and treatment – Evidence based up to 2013. Otolaryngologia Polska, 2014, 68, 1-14.	0.2	28
538	Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost (SIB-VMAT): An analysis for complex head-neck, high-risk prostate and rectal cancer cases. Medical Dosimetry, 2014, 39, 108-116.	0.4	23
539	Dorsal vagal complex of the brainstem: Conformal avoidance to reduce nausea. Practical Radiation Oncology, 2014, 4, 267-271.	1.1	7
540	Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. Oral Oncology, 2014, 50, 513-519.	0.8	62
541	Head and Neck Cancers, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1454-1487.	2.3	192
542	Longâ€term experience with reduced planning target volume margins and intensityâ€modulated radiotherapy with daily imageâ€guidance for head and neck cancer. Head and Neck, 2014, 36, 1766-1772.	0.9	46
543	Investigating the clinical advantages of a robotic linac equipped with a multileaf collimator in the treatment of brain and prostate cancer patients. Journal of Applied Clinical Medical Physics, 2015, 16, 284-295.	0.8	42
544	A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. Radiation Oncology, 2015, 10, 166.	1.2	26
545	Radiation dose response simulation for biomechanical-based deformable image registration of head and neck cancer treatment. Physics in Medicine and Biology, 2015, 60, 8481-8489.	1.6	10
546	Effect of induction chemotherapy on swallow physiology and saliva production in patients with head and neck cancer: A pilot study. Head and Neck, 2015, 37, 567-572.	0.9	11
547	Evaluation of an automated knowledge based treatment planning system for head and neck. Radiation Oncology, 2015, 10, 226.	1.2	94
548	Potential advantages of volumetric arc therapy in head and neck cancer. Head and Neck, 2015, 37, 909-914.	0.9	18

#	Article	IF	CITATIONS
549	Effects of Salivary Secretion Stimulation on the Treatment of Chronic Radioactive Iodine-Induced Sialadenitis. Thyroid, 2015, 25, 839-845.	2.4	11
551	Complications of Head and Neck Radiotherapy and Management. , 2015, , 221-232.		1
553	Parotid gland shrinkage during IMRT predicts the time to Xerostomia resolution. Radiation Oncology, 2015, 10, 19.	1.2	23
554	Complication of Oral Cancer Treatment, Prevention, and Management. , 2015, , 335-344.		1
555	Parotid glands in whole-brain radiotherapy: 2D versus 3D technique for no sparing or sparing. Radiologia Medica, 2015, 120, 324-328.	4.7	10
556	Oropharyngeal Cancer. , 2015, , 171-192.		0
558	Toward a more patient-specific model of post-radiotherapy saliva secretion for head and neck cancer patients. Acta Oncol \tilde{A}^3 gica, 2015, 54, 1310-1316.	0.8	5
559	Simple tool for prediction of parotid gland sparing in intensity-modulated radiation therapy. Medical Dosimetry, 2015, 40, 232-234.	0.4	6
560	PO-0982: The impact of plan complexity on the accuracy of VMAT for the treatment of head and neck cancer. Radiotherapy and Oncology, 2015, 115, S524.	0.3	2
561	Predicting the need for adaptive radiotherapy in head and neck cancer. Radiotherapy and Oncology, 2015, 116, 57-63.	0.3	68
562	Mesenchymal stem cells – A new hope for radiotherapy-induced tissue damage?. Cancer Letters, 2015, 366, 133-140.	3.2	83
564	Improving target dose coverage and organ-at-risk sparing in intensity-modulated radiotherapy of advanced laryngeal cancer by a simple optimization technique. British Journal of Radiology, 2015, 88, 20140654.	1.0	7
565	Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Radiation-Induced Xerostomia: Results of RTOG 0537 Phase 3 Study. International Journal of Radiation Oncology Biology Physics, 2015, 92, 220-227.	0.4	39
566	Assessment and topographic characterization of locoregional recurrences in head and neck tumours. Radiation Oncology, 2015, 10, 41.	1.2	12
567	Prospective longitudinal assessment of parotid gland function using dynamic quantitative pertechnate scintigraphy and estimation of dose–response relationship of parotid-sparing radiotherapy in head-neck cancers. Radiation Oncology, 2015, 10, 67.	1.2	20
568	Regenerative Medicine in Otolaryngology. , 2015, , .		1
570	Intensity-Modulated Radiation Therapy. , 2015, , .		7
572	Therapy-Induced Changes in Head and Neck. Medical Radiology, 2015, , 95-111.	0.0	3

#	Article	IF	CITATIONS
573	Weekly kilovoltage cone-beam computed tomography for detection of dose discrepancies during (chemo)radiotherapy for head and neck cancer. Acta Oncológica, 2015, 54, 1483-1489.	0.8	10
574	Radiotherapy-induced salivary dysfunction: Structural changes, pathogenetic mechanisms and therapies. Archives of Oral Biology, 2015, 60, 1802-1810.	0.8	51
575	Usefulness of Magnetic Resonance Sialography for the Evaluation of Radioactive Iodine-Induced Sialadenitis. Annals of Surgical Oncology, 2015, 22, 1007-1013.	0.7	14
576	Evaluation of Parotid Gland Dose Rate following Intensity Modulated Radiation Therapy in Head and Neck Cancer. Spectroscopy Letters, 2015, 48, 217-221.	0.5	0
577	Semiautomated headâ€andâ€neck IMRT planning using dose warping and scaling to robustly adapt plans in a knowledge database containing potentially suboptimal plans. Medical Physics, 2015, 42, 4428-4434.	1.6	19
578	Novel Manganese-Porphyrin Superoxide Dismutase-Mimetic Widens the Therapeutic Margin in a Preclinical Head and Neck Cancer Model. International Journal of Radiation Oncology Biology Physics, 2015, 93, 892-900.	0.4	61
579	Impact of Node Negative Target Volume Delineation on Contralateral Parotid Gland Dose Sparing Using IMRT in Head and Neck Cancer. Technology in Cancer Research and Treatment, 2015, 14, 315-319.	0.8	0
580	Comparison of swallowing function after intensity-modulated radiation therapy and conventional radiotherapy for head and neck cancer. Head and Neck, 2015, 37, 1575-1582.	0.9	44
581	Dry Mouth. , 2015, , .		5
582	Radiation Therapy for Head and Neck Cancers. , 2015, , .		6
583	The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2015, 49, 278-287.	2.9	49
584	Healthcare Analytics: From Data to Knowledge to Healthcare Improvement. , 2016, , .		12
585	Two-stage autotransplantation of the human submandibular gland: First long-term results. Laryngoscope, 2016, 126, 1551-1555.	1.1	5
586	Prospective investigation and literature review of tolerance dose on salivary glands using quantitative salivary gland scintigraphy in the intensityâ€modulated radiotherapy era. Head and Neck, 2016, 38, E1746-55.	0.9	13
587	Use of regularized principal component analysis to model anatomical changes during head and neck radiation therapy for treatment adaptation and response assessment. Medical Physics, 2016, 43, 5307-5319.	1.6	9
588	Late Effects after Radiation. , 2016, , 253-274.e6.		2
589	Dose-volume relationships for moderate or severe neck muscle atrophy after intensity-modulated radiotherapy in patients with nasopharyngeal carcinoma. Scientific Reports, 2016, 5, 18415.	1.6	7
590	Current Concepts in Osteoradionecrosis after Head and Neck Radiotherapy. Clinical Oncology, 2016, 28, 459-466.	0.6	59

#	Article	IF	CITATIONS
591	Establishing a targeted plan for prophylactic dental extractions in patients with laryngeal cancer receiving adjuvant radiotherapy. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 122, 43-49.	0.2	7
593	Salivary gland-sparing helical tomotherapy for head and neck cancer: Preserved salivary function on quantitative salivary gland scintigraphy after tomotherapy. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2016, 133, 257-262.	0.4	7
595	Impact of xerostomia and dysphagia on health-related quality of life for head and neck cancer patients. Expert Review of Quality of Life in Cancer Care, 2016, 1, 361-371.	0.6	5
596	Magnetic nanoparticles-based acoustical detection and hyperthermic treatment of cancer, <i>in vitro </i> and <i>in vivo </i> studies. Journal of Nanophotonics, 2016, 10, 036007.	0.4	5
598	Accuracy of software-assisted contour propagation from planning CT to cone beam CT in head and neck radiotherapy. Acta $Oncol\tilde{A}^3$ gica, 2016 , 55 , $1324-1330$.	0.8	19
599	IMRT for head and neck cancer: reducing xerostomia and dysphagia. Journal of Radiation Research, 2016, 57, i69-i75.	0.8	93
603	Predictive Modeling in Radiation Oncology. , 2016, , 189-219.		0
604	Evaluation of radiotherapy techniques for radical treatment of lateralised oropharyngeal cancers. Strahlentherapie Und Onkologie, 2016, 192, 516-525.	1.0	9
605	Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy. Clinical Oncology, 2016, 28, e69-e76.	0.6	26
606	Reduction of xerostomia in head and neck cancer patients. A critical review of the literature. Radiography, 2016, 22, S57-S63.	1.1	2
607	Acute toxicity in comprehensive head and neck radiation for nasopharynx and paranasal sinus cancers: cohort comparison of 3D conformal proton therapy and intensity modulated radiation therapy. Radiation Oncology, 2016, 11, 32.	1.2	60
608	Dosimetric and Clinical Outcomes With Intensity Modulated Radiation Therapy After Chemotherapy for Patients With Early-Stage Diffuse Large B-cell Lymphoma of Waldeyer Ring. International Journal of Radiation Oncology Biology Physics, 2016, 96, 379-386.	0.4	6
609	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 102, 47-54.	2.0	51
610	Unilateral and bilateral neck SIB for head and neck cancer patients. Strahlentherapie Und Onkologie, 2016, 192, 232-239.	1.0	21
611	Comparative treatment planning study on sequential vs. simultaneous integrated boost in head and neck cancer patients. Strahlentherapie Und Onkologie, 2016, 192, 17-24.	1.0	14
612	Oropharyngeal Cancer. , 2016, , 597-628.e6.		1
614	Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. Critical Reviews in Oncology/Hematology, 2016, 97, 131-142.	2.0	82
615	Mucosal Sparing Radiation Therapy in Resected Oropharyngeal Cancer. Annals of Otology, Rhinology and Laryngology, 2017, 126, 185-191.	0.6	9

#	Article	IF	CITATIONS
619	The outcome of the first 100 nasopharyngeal cancer patients in thailand treated by helical tomotherapy. Radiology and Oncology, 2017, 51, 351-356.	0.6	1
620	Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1022-1027.	0.4	18
622	Volumetric-modulated arc therapy (VMAT) for whole brain radiotherapy: not only for hippocampal sparing, but also for reduction of dose to organs at risk. Medical Dosimetry, 2017, 42, 375-383.	0.4	27
623	Clinical outcomes of concurrent chemoradiotherapy with volumetric modulated arc therapy in patients with locally advanced nasopharyngeal carcinoma. Japanese Journal of Radiology, 2017, 35, 673-680.	1.0	2
624	Dose–volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer. Radiotherapy and Oncology, 2017, 124, 240-247.	0.3	20
625	Patient reported outcome and experience measures of oral disease in oral medicine. British Dental Journal, 2017, 223, 713-713.	0.3	15
626	Acute toxicity of concomitant boost radiation therapy by volumetric-modulated arc therapy in head and neck cancers. Journal of Radiotherapy in Practice, 2017, 16, 423-430.	0.2	0
627	Modern radiotherapy techniques versus three-dimensional conformal radiotherapy for head and neck cancer. The Cochrane Library, 0, , .	1.5	4
628	Volumetric modulated arc therapy for treatment of solid tumors: current insights. OncoTargets and Therapy, 2017, Volume 10, 3755-3772.	1.0	33
629	Can Intensity-Modulated-Radiotherapy Reduce Toxicity in Head and Neck Squamous Cell Carcinoma?. Cancers, 2017, 9, 135.	1.7	49
630	Clinical features and preventive therapies of radiation-induced xerostomia in head and neck cancer patient: a literature review. Applied Cancer Research, 2017, 37, .	1.0	18
631	Concomitant-chemoradiotherapy-associated oral lesions in patients with oral squamous-cell carcinoma. Cancer Biology and Medicine, 2017, 14, 176.	1.4	17
632	Multidisciplinary Care of the Head and Neck Cancer Patient. Cancer Treatment and Research, 2018, , .	0.2	10
633	Salivary flow rate after conventional and intensity-modulated radiation therapy. Journal of the American Dental Association, 2018, 149, 432-441.	0.7	7
634	Radiation Therapy for the Head and Neck Patient: Advances, Challenges, and Perspectives. Cancer Treatment and Research, 2018, 174, 145-162.	0.2	2
635	Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT. Radiologia Medica, 2018, 123, 415-423.	4.7	46
636	Pre-Radiation dental considerations and management for head and neck cancer patients. Oral Oncology, 2018, 76, 42-51.	0.8	30
638	Hazards of sparing the ipsilateral parotid gland in the node-positive neck with intensity modulated radiation therapy: Spatial analysis of regional recurrence risk. Advances in Radiation Oncology, 2018, 3, 111-120.	0.6	4

#	Article	IF	CITATIONS
639	A randomized phaseÂllI study between sequential versus simultaneous integrated boost intensity-modulated radiation therapy in nasopharyngeal carcinoma. Strahlentherapie Und Onkologie, 2018, 194, 375-385.	1.0	30
640	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
641	Effects of biodegradable hydrogel spacer injection on contralateral submandibular gland sparing in radiotherapy for head and neck cancers. Radiotherapy and Oncology, 2018, 126, 96-99.	0.3	14
642	Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life. Radiotherapy and Oncology, 2018, 126, 68-74.	0.3	74
643	Organ-Sparing in Radiotherapy for Head-and-Neck Cancer: Improving Quality of Life. Seminars in Radiation Oncology, 2018, 28, 46-52.	1.0	38
644	Study of dosimetric indices and dose constraints to critical organs for head and neck tumours treated with inverse planned simultaneous integrated boost intensity-modulated radiotherapy. Journal of Radiotherapy in Practice, 2018, 17, 179-187.	0.2	0
645	Comparison of intensity modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) and a 3-dimensional conformal parotid gland-sparing radiotherapy (ConPas 3D-CRT) in treatment of nasopharyngeal carcinoma: a mono-institutional experience. Radiologia Medica, 2018, 123, 217-226.	4.7	7
646	Cone-beam computed tomography (CBCT) for adaptive image guided head and neck radiation therapy. Acta Oncol \tilde{A}^3 gica, 2018, 57, 552-556.	0.8	35
647	A model for predicting the dose to the parotid glands based on their relative overlapping with planning target volumes during helical radiotherapy. Journal of Applied Clinical Medical Physics, 2018, 19, 48-53.	0.8	15
648	Volumetric decrease of pancreas after abdominal irradiation, it is time to consider pancreas as an organ at risk for radiotherapy planning. Radiation Oncology, 2018, 13, 238.	1.2	22
649	Postoperative radiotherapy for T1/2N0M0 mucoepidermoid carcinoma positive for CRTC1/3â€MAML2 fusions. Head and Neck, 2018, 40, 2565-2573.	0.9	8
650	Can We Expect Less Toxicities with Newer Forms of Radiotherapy?., 2018,, 181-212.		0
652	Dysphagia Management in Head and Neck Cancers. , 2018, , .		5
653	Objective and subjective hyposalivation after treatment for head and neck cancer: Longâ€ŧerm outcomes. Laryngoscope, 2018, 128, 2732-2739.	1.1	21
654	Planning comparison of five automated treatment planning solutions for locally advanced head and neck cancer. Radiation Oncology, 2018, 13, 170.	1.2	30
655	Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase III randomized trial. Journal of Radiation Research, 2018, 59, 446-455.	0.8	26
656	A planning study to optimise a simultaneously integrated boost treatment of larynx cancer with seven intensity-modulated radiation therapy (IMRT) beams. Journal of Radiotherapy in Practice, 2018, 17, 447-454.	0.2	1
657	Evaluation of Salivary Gland Function Using Diffusion-Weighted Magnetic Resonance Imaging for Follow-Up of Radiation-Induced Xerostomia. Korean Journal of Radiology, 2018, 19, 758.	1.5	19

#	Article	IF	CITATIONS
658	Design and Selection of Machine Learning Methods Using Radiomics and Dosiomics for Normal Tissue Complication Probability Modeling of Xerostomia. Frontiers in Oncology, 2018, 8, 35.	1.3	115
660	Advanced Oromandibular Cancer. , 2018, , 475-531.		0
661	Advanced HPV-Unrelated Pharynx Cancer. , 2018, , 700-760.		0
662	Locoregional Control and Toxicity in Head and Neck Carcinoma Patients following Helical Tomotherapy-Delivered Intensity-Modulated Radiation Therapy Compared with 3D-CRT Data. Oncology, 2018, 95, 61-68.	0.9	12
663	Early Prediction of Acute Xerostomia During Radiation Therapy for Head and Neck Cancer Based on Texture Analysis of Daily CT. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1308-1318.	0.4	26
664	Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. Supportive Care in Cancer, 2019, 27, 573-581.	1.0	5
665	MultiRBE: Treatment planning for protons with selective radiobiological effectiveness. Medical Physics, 2019, 46, 4276-4284.	1.6	17
666	Eliminating Postoperative Radiation to the Pathologically Node-Negative Neck: Long-Term Results of a Prospective Phase II Study. Journal of Clinical Oncology, 2019, 37, 2548-2555.	0.8	49
667	Advancing Care for Head and Neck Cancers in a Multidisciplinary Tumour Board in the East. Clinical Oncology, 2019, 31, 549-559.	0.6	2
668	Clinical and dosimetric predictors of physician and patient reported xerostomia following intensity modulated radiotherapy for nasopharyngeal cancer – A prospective cohort analysis. Radiotherapy and Oncology, 2019, 138, 149-157.	0.3	16
669	Relationship between patient and physician-rated xerostomia and dose distribution to the oral cavity and salivary glands for head and neck cancer patients after radiotherapy. Acta Oncol \tilde{A}^3 gica, 2019, 58, 1366-1372.	0.8	16
670	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 567-580.	0.4	96
671	Salivary Gland Hypofunction and Xerostomia in Head and Neck Radiation Patients. Journal of the National Cancer Institute Monographs, 2019, 2019, .	0.9	107
672	Ability to Propose Optimal Prosthetic Rehabilitation can be Improved by Discussion between the Dentist and Radiation Oncologist Regarding Upstream Dosimetry. European Journal of Dentistry, 2019, 13, 088-094.	0.8	2
673	Incorporation of Dosimetric Gradients and Parotid Gland Migration Into Xerostomia Prediction. Frontiers in Oncology, 2019, 9, 697.	1.3	2
674	Recent advances in radiotherapy and its associated side effects in cancer—a review. Journal of Basic and Applied Zoology, 2019, 80, .	0.4	63
675	Dose-volume relationship for laryngeal substructures and aspiration in patients with locally advanced head-and-neck cancer. Radiation Oncology, 2019, 14, 49.	1.2	12
676	Patient perspectives and treatment regret after deâ€escalated chemoradiation for human papillomavirusâ€positive oropharyngeal cancer: Findings from a phase II trial. Head and Neck, 2019, 41, 2768-2776.	0.9	5

#	Article	IF	CITATIONS
677	Radiomics and Machine Learning for Radiotherapy in Head and Neck Cancers. Frontiers in Oncology, 2019, 9, 174.	1.3	85
678	Skin DVHs predict cutaneous toxicity in Head and Neck Cancer patients treated with Tomotherapy. Physica Medica, 2019, 59, 133-141.	0.4	17
679	Acupuncture for patients with cancer-induced xerostomia: a systematic review protocol. BMJ Open, 2019, 9, e031892.	0.8	4
680	Aperture Shape Generation Based on Gradient Descent With Momentum. IEEE Access, 2019, 7, 157623-157632.	2.6	7
681	Predictors for improvement of xerostomia in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Medicine (United States), 2019, 98, e17030.	0.4	12
682	Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer. JAMA Network Open, 2019, 2, e1916910.	2.8	49
683	Monitoring anatomical changes of individual patients using statistical process control during head-and-neck radiotherapy. Physics and Imaging in Radiation Oncology, 2019, 9, 21-27.	1.2	10
684	Radiationâ€induced nausea and vomiting in head and neck cancer: Is it something worth considering in the intensity modulated radiotherapy era? "A narrative reviewâ€i Head and Neck, 2020, 42, 131-137.	0.9	7
685	Cancer of the Head and Neck. , 2020, , 999-1033.e7.		3
686	Dental caries following radiotherapy for head and neck cancer: A systematic review. Oral Oncology, 2020, 100, 104484.	0.8	56
687	Intensity-Modulated Radiation Therapy Optimization for Acceptable and Remaining-One Unacceptable Dose-Volume and Mean-Dose Constraint Planning. Computational and Mathematical Methods in Medicine, 2020, 2020, 1-14.	0.7	0
689	Recommendation regarding the cranial upper border of level IIb in delineating clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiation Oncology, 2020, 15, 270.	1.2	4
690	Prognostic impact of CRTC1/3â€MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study. Cancer Science, 2020, 111, 4195-4204.	1.7	20
691	Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial. Radiation Oncology, 2020, 15, 218.	1.2	38
692	Radiation-Induced Salivary Gland Dysfunction: Mechanisms, Therapeutics and Future Directions. Journal of Clinical Medicine, 2020, 9, 4095.	1.0	76
693	Acupuncture for Radiation-Induced Xerostomia in Cancer Patients: A Systematic Review and Meta-Analysis. Integrative Cancer Therapies, 2020, 19, 153473542098082.	0.8	21
695	Clinical implication in the use of the AAA algorithm versus the AXB in nasopharyngeal carcinomas by comparison of TCP and NTCP values. Radiation Oncology, 2020, 15, 150.	1.2	6
696	Saliva electrolyte analysis and xerostomia-related quality of life in nasopharyngeal carcinoma patients following intensity-modulated radiation therapy. Radiotherapy and Oncology, 2020, 150, 97-103.	0.3	22

#	ARTICLE	IF	Citations
697	Most Cited Articles in Head and Neck Oncology. Ear, Nose and Throat Journal, 2020, 100, 014556132093492.	0.4	2
698	Dose accumulation to assess the validity of treatment plans with reduced margins in radiotherapy of head and neck cancer. Physics and Imaging in Radiation Oncology, 2020, 14, 53-60.	1.2	8
699	Correlation of intensity-modulated radiation therapy at a specific radiation dose with the prognosis of nasal mucous damage after radiotherapy. Radiation and Environmental Biophysics, 2020, 59, 245-255.	0.6	9
701	Adaptive radiotherapy for head and neck cancer. Cancers of the Head & Neck, 2020, 5, 1.	6.2	93
702	Sticky stuff: xerostomia in patients undergoing head and neck radiotherapyâ€"prevalence, prevention, and palliative care. Annals of Palliative Medicine, 2020, 9, 1340-1350.	0.5	7
703	P2 Receptors as Therapeutic Targets in the Salivary Gland: From Physiology to Dysfunction. Frontiers in Pharmacology, 2020, 11, 222.	1.6	18
704	Salivary Gland Embryology, Physiology, and Stem Cell Complexity. , 2021, , 12-18.		0
705	Shortâ€ŧerm and longâ€ŧerm unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma. Head and Neck, 2021, 43, 456-466.	0.9	1
706	Vitamin D oral gel for prevention of radiationâ€induced oral mucositis: A randomized clinical trial. Oral Diseases, 2021, 27, 1197-1204.	1.5	10
707	Saliva substitute mouthwash in nasopharyngeal cancer survivors with xerostomia: a randomized controlled trial. Clinical Oral Investigations, 2021, 25, 3105-3115.	1.4	11
708	Examination of the best head tilt angle to reduce the parotid gland dose maintaining a safe level of lens dose in wholeâ€brain radiotherapy using the fourâ€field box technique. Journal of Applied Clinical Medical Physics, 2021, 22, 49-57.	0.8	2
709	Xerostomia and hyposalivation among a 65â€yrâ€old population living in Oslo, Norway. European Journal of Oral Sciences, 2021, 129, e12757.	0.7	31
710	Mean parotid dose prediction model using machine learning regression method for intensity-modulated radiotherapy in head and neck cancer. Medical Dosimetry, 2021, 46, 283-288.	0.4	5
711	Prevalence of hyposalivation and associated factors in survivors of head and neck cancer treated with radiotherapy. Journal of Applied Oral Science, 2021, 29, e20200854.	0.7	7
712	Study of dosimetry and clinical factors for assessment of xerostomia in head and neck squamous cell carcinoma treated by intensity-modulated radiotherapy: A prospective study. Journal of Carcinogenesis, 2021, 20, 14.	2.5	1
713	A case of metachronous bilateral secretory carcinoma. Rare Tumors, 2021, 13, 203636132110091.	0.3	3
714	Risk of second primary malignancy after minor salivary gland cancer: A Surveillance, Epidemiology, and End Results database analysis. Head and Neck, 2021, 43, 1769-1779.	0.9	5
715	Durability of the parotidâ€sparing effect of intensityâ€modulated radiotherapy (<scp>IMRT</scp>) in early stage nasopharyngeal carcinoma: A 15â€year followâ€up of a randomized prospective study of <scp>IMRT</scp> versus twoâ€dimensional radiotherapy. Head and Neck, 2021, 43, 1711-1720.	0.9	10

#	Article	IF	CITATIONS
716	Significance of siteâ€specific radiation dose and technique for success of implantâ€based prosthetic rehabilitation in irradiated head and neck cancer patientsâ€"A cohort study. Clinical Implant Dentistry and Related Research, 2021, 23, 444-455.	1.6	8
717	Determining Clinical Patient Selection Guidelines for Head and Neck Adaptive Radiation Therapy Using Random Forest Modelling and a Novel Simplification Heuristic. Frontiers in Oncology, 2021, 11, 650335.	1.3	5
718	Acupuncture for radiation-induced toxicity in head and neck squamous cell carcinoma: a systematic review based on PICO criteria. European Archives of Oto-Rhino-Laryngology, 2022, 279, 2083-2097.	0.8	5
719	Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. Radiotherapy and Oncology, 2021, 160, 32-39.	0.3	18
720	Determinants of patientâ€reported xerostomia among longâ€term oropharyngeal cancer survivors. Cancer, 2021, 127, 4470-4480.	2.0	14
721	Baş-Boyun Kanseri Yoğunluk Ayarlı Radyoterapisinde Parotis Bezi Hacmi ve Hedef Hacim İlişkilerinin Paroti Bezi Dozuna Etkisi. Sþleyman Demirel Āœniversitesi Tıp Fakültesi Dergisi, 0, , .	S _{0.0}	0
722	A Predictive Model for Reactive Tube Feeding in Head and Neck Cancer Patients Undergoing Definitive (Chemo) Radiotherapy. Clinical Oncology, 2021, 33, e433-e441.	0.6	8
723	Application of regenerative medicine to salivary gland hypofunction. Japanese Dental Science Review, 2021, 57, 54-59.	2.0	13
724	Regenerative Approaches in Oral Medicine. , 2021, , 197-264.		0
725	IMRT for Paranasal Sinus and Nasal Cavity (Sino-Nasal) Tumors. , 2006, , 289-299.		2
726	Strategies for Protecting Normal Tissue in the Treatment of Head and Neck Cancer., 2005,, 227-237.		3
727	Xerostomia. , 2007, , 185-199.		1
728	Salivary Glands and Quality of Life. Medical Radiology, 2009, , 89-101.	0.0	1
729	Nonsurgical Treatment of Head and Neck Cancer. , 2011, , 2893-2914.		3
730	Early to late sparing of radiation damage to the parotid gland by adrenergic and muscarinic receptor agonists. British Journal of Cancer, 2001, 85, 1055-1063.	2.9	8
731	Using Multivariate Regression Model with Least Absolute Shrinkage and Selection Operator (LASSO) to Predict the Incidence of Xerostomia after Intensity-Modulated Radiotherapy for Head and Neck Cancer. PLoS ONE, 2014, 9, e89700.	1.1	74
732	IMRT with the Use of Simultaneous Integrated Boost in Treatment of Head and Neck Cancer: Acute Toxicity Evaluation. Acta Medica (Hradec Kralove), 2006, 49, 167-173.	0.2	7
733	Prognostic nomogram of xerostomia for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy. Aging, 2020, 12, 1857-1866.	1.4	8

#	Article	IF	CITATIONS
734	Parotid gland sparing effect by computed tomography-based modified lower field margin in whole brain radiotherapy. Radiation Oncology Journal, 2013, 31, 12.	0.7	14
735	Intensity-modulated radiation therapy in early stage squamous cell carcinoma of the larynx: treatment trends and outcomes. Radiation Oncology Journal, 2020, 38, 11-17.	0.7	11
736	Promising Gene Therapeutics for Salivary Gland Radiotoxicity. AIMS Medical Science, 2016, 3, 329-344.	0.2	4
737	Comparative study of four advanced 3d-conformal radiation therapy treatment planning techniques for head and neck cancer. Journal of Medical Physics, 2013, 38, 98-105.	0.1	14
738	Radiobiological evaluation of intensity modulated radiation therapy treatments of patients with head and neck cancer: A dual-institutional study. Journal of Medical Physics, 2015, 40, 165.	0.1	3
739	A quality index for equivalent uniform dose. Journal of Medical Physics, 2011, 36, 126.	0.1	15
740	Dose volume histogram analysis and comparison of different radiobiological models using in-house developed software. Journal of Medical Physics, 2011, 36, 220.	0.1	55
741	Radiation-induced dental caries, prevention and treatment - A systematic review. National Journal of Maxillofacial Surgery, 2015, 6, 160.	0.1	98
742	Objective and subjective assessment of xerostomia in patients of locally advanced head-and-neck cancers treated by intensity-modulated radiotherapy. Journal of Cancer Research and Therapeutics, 2018, 14, 1196-1201.	0.3	7
743	Evaluation of Parotid Gland Function following Intensity Modulated Radiation Therapy for Head and Neck Cancer. Cancer Research and Treatment, 2006, 38, 84.	1.3	13
744	Influence of bethanechol on salivary parameters in irradiated patients. Medicina Oral, Patologia Oral Y Cirugia Bucal, 2016, 22, 0-0.	0.7	2
745	Mechanism, Prevention, and Treatment of Radiation-Induced Salivary Gland Injury Related to Oxidative Stress. Antioxidants, 2021, 10, 1666.	2.2	11
746	Evaluating dysphagia and xerostomia outcomes following transoral robotic surgery for patients with oropharyngeal cancer. Head and Neck, 2021, 43, 3955-3965.	0.9	1
747	Clinical Use of IMRT:Now and the Future. Japanese Journal of Radiological Technology, 2001, 57, 516-522.	0.0	1
750	On the Risks of a Constant RBE for Proton Treatment Planning. IFMBE Proceedings, 2009, , 76-79.	0.2	0
751	Interfractional Variations of Shape and Impact on Dose of Organs at Risk in Head and Neck Cancer Patients during Helical Tomotherapy. IFMBE Proceedings, 2009, , 591-594.	0.2	0
752	Adaptive Image-Guided Radiotherapy for Head and Neck Cancer. Medical Radiology, 2009, , 183-190.	0.0	1
7 53	Improving the Quality of Life of Patients with Head and Neck Cancer by Highly Conformal Radiotherapy. Medical Radiology, 2009, , 145-153.	0.0	0

#	Article	IF	Citations
754	Late Radiation-Induced Side Effects. Medical Radiology, 2009, , 227-241.	0.0	0
755	Cancer of the Oropharynx. , 2010, , 546-587.		0
758	Cancer of the Hypopharynx. , 2010, , 613-641.		0
759	Long-Term Complications in the Treatment of Nasopharyngeal Carcinoma. Medical Radiology, 2010, , 275-294.	0.0	0
760	Cancer of the Nasopharynx. , 2010, , 523-545.		0
761	Approaches to Supportive Care. , 2011, , 255-265.		0
762	Normal Tissue Complications and Protection in Head and Neck Cancer Patients. , 2011, , 613-628.		0
763	Carcinoma del rinofaringe. , 2011, , 293-307.		0
764	Oropharyngeal Cancer., 2012,, 585-617.		0
766	Conformal Therapy and Intensity-Modulated Radiation Therapy. , 2012, , 287-316.		2
767	Survivorship and Late Effects. , 2012, , 239-256.		2
768	Machine Learning Applications in Radiation Therapy. , 2012, , 59-84.		0
769	The Cytoprotective Effect of Amifostine Against Radiation Induced Toxicity. , 0, , .		0
770	The Usability Analysis of 3D-CRT, IMRT, Tomotherpy Radiation Therapy on Nasopharyngeal Cancer. Journal of the Korean Society of Radiology, 2012, 6, 365-371.	0.0	3
771	IntensitÃ t smodulierte Strahlentherapie. , 2013, , 271-286.		1
772	Tumor Geometrical Deformation Modeling. Engineering and Management Innovation, 2013, , 141-164.	0.1	0
773	Complications Associated with Radiotherapy. , 2014, , 147-152.		0
774	Late Oral Adverse Effects of Cancer Treatments. Medical Radiology, 2014, , 141-166.	0.0	1

#	Article	IF	CITATIONS
776	Upper Respiratory and Digestive System: Pharynx, Larynx, and Xerostomia. Medical Radiology, 2014, , 167-188.	0.0	О
777	Cancer of the Head and Neck. , 2014, , 1037-1070.e6.		1
778	New Radiotherapy Techniques for the Prevention of Radiotherapy-Induced Xerostomia., 2015, , 147-164.		0
779	Salivary Gland Development and Regeneration. , 2015, , 209-223.		0
781	Normal Tissue Complications and Protection in Head and Neck Cancer Patients. , 2016, , 753-767.		0
782	A Case of a Large, Invasive PTC with Gross Residual Disease (pT4) After Surgery. , 2016, , 213-219.		0
783	Functional Impairments after Neck Dissection and Adjuvant Treatment: Patterns of Care. International Journal of Physical Medicine & Rehabilitation, 2016, 4, .	0.5	0
784	Can xerostomia be further reduced by sparing parotid stem cells?. Annals of Translational Medicine, 2016, 4, S16-S16.	0.7	1
785	Differences in Parotid Dosimetry and Expected Normal Tissue Complication Probabilities in Whole Brain Radiation Plans Covering C1 Versus C2. Cureus, 2017, 9, e1217.	0.2	3
786	Preventive Strategies in Radiation-Associated Dysphagia. , 2018, , 321-331.		0
787	Intensity-modulated radiation therapy reduces late salivary toxicity and mandibular osteoradionecrosis in the treatment of oral cavity cancer: retrospective study. Journal of Surgery and Medicine, 0, , .	0.0	0
788	Dry mouth: An emerging epidemic. Journal of Datta Meghe Institute of Medical Sciences University, 2019, 14, 279.	0.0	0
789	Comparison of Fluoride Ion Release from Fluoride Gel in Various Solvents. Acta Stomatologica Croatica, 2020, 54, 147-154.	0.4	3
790	The secretory senescence of the oro-pharyngo-laryngeal tract. Journal of Gerontology and Geriatrics, 2020, 68, 69-76.	0.2	2
791	Techniques of Whole Brain Radiation Therapy Including Hippocampal Avoidance., 2020,, 347-367.		0
792	Parotid sparing and quality of life in long-term survivors of locally advanced head and neck cancer after intensity-modulated radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 219-230.	1.0	10
793	Chemoradiotherapy in Oral Cavity Cancer. Textbooks in Contemporary Dentistry, 2020, , 291-301.	0.2	1
794	Toxicity Management for Head and Neck Tumors in Radiation Oncology-I. , 2020, , 59-83.		0

#	Article	IF	CITATIONS
795	Intensity-Modulated Radiation Therapy in the Management of Head and Neck Cancer., 2005, , 115-124.		1
797	Does Dose Volume Histogram of Parotid Glands Correlate with Xerostomia Radiation Therapy Oncology Group Scores in Locoregionally Advanced Head and Neck Cancer Patients Treated with Intensity-Modulated Radiation Therapy?. Asian Journal of Oncology, 0, 07, 118-125.	0.2	0
798	Impact of geometric uncertainties on dose distribution during intensity modulated radiotherapy of head-and-neck cancer: the need for a planning target volume and a planning organ-at-risk volume. Current Oncology, 2006, 13, 108-15.	0.9	20
799	Adjuvant chemoradiation for localized rectal cancer: current trends and future directions. Gastrointestinal Cancer Research: GCR, 2007, 1, S64-72.	0.8	1
801	Hazards and risks in oncology: radiation oncology. GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery, 2013, 12, Doc03.	0.8	4
802	Late Oral Complications Caused by Head and Neck Radiotherapy: Clinical and Laboratory Study. Journal of Oral $\&$ Maxillofacial Research, 2020, 11 , e3.	0.3	1
803	Late Oral Complications Caused by Head and Neck Radiotherapy: Clinical and Laboratory Study. Journal of Oral $\&$ Maxillofacial Research, 2020, 11 , e3.	0.3	7
804	Salivary Gland Diseases, Hyposalivation, and Xerostomia in Head and Neck Cancer Patients., 2022, , 115-126.		1
805	Mathematical evaluation of post-radiotherapy salivary gland function using salivary gland scintigraphy. British Journal of Radiology, 2022, 95, 20210718.	1.0	3
806	Assessment of hyperbaric oxygenation treatment response in parotid glands by <i>T</i> ₂ mapping following radiotherapy for head and neck tumours. Radiology and Oncology, 2022, 56, 60-68.	0.6	0
807	Comparison of effects of dexmedetomidine and amifostine against X-ray radiation-induced parotid damage. Radiation and Environmental Biophysics, 2022, 61, 241-253.	0.6	5
808	Organs at risk radiation dose constraints. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 59-75.	0.6	29
809	Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. Journal of Nuclear Medicine, 2021, 62, 23S-35S.	2.8	32
810	Online adaptive radiotherapy of urinary bladder cancer with full re-optimization to the anatomy of the day: Initial experience and dosimetric benefits. Radiotherapy and Oncology, 2022, 171, 37-42.	0.3	35
811	The impact of head and neck radiotherapy on salivary flow and quality of life: Results of the ORARAD study. Oral Oncology, 2022, 127, 105783.	0.8	12
812	Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Scientific Reports, 2022, 12, 6662.	1.6	2
814	De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma—Where Are We Now?. Current Oncology, 2022, 29, 3668-3697.	0.9	8
815	The First Prognostic Tool to Estimate the Risk of Late Grade ≥3 Xerostomia in Patients Irradiated for Head-and-Neck Cancer. Anticancer Research, 2022, 42, 3035-3039.	0.5	0

#	ARTICLE	IF	CITATIONS
816	Prognostic Factors for Complete Recovery From Xerostomia After Radiotherapy of Head-and-Neck Cancers. In Vivo, 2022, 36, 1795-1800.	0.6	5
817	Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study. Radiotherapy and Oncology, 2022, 175, 1-9.	0.3	7
818	Impact of Dose-Volume Parameters of Parotid Glands on Xerostomia in Patients Irradiated for Head-and-Neck Cancer. Anticancer Research, 2022, 42, 3551-3556.	0.5	1
819	Research Value of Intensity Modulated Radiation Therapy in Alleviating Parotid Gland Function Injury in Patients with Stage NO Nasopharyngeal Carcinoma from Physical and Dosimetric Aspects. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-7.	0.7	3
820	Parameters of the Lyman model for calculation of normal tissue complication probability: a systematic literature review. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	2
821	Salivary Gland Toxicity of PSMA-Targeted Radioligand Therapy with 177Lu-PSMA and Combined 225Ac- and 177Lu-Labeled PSMA Ligands (TANDEM-PRLT) in Advanced Prostate Cancer: A Single-Center Systematic Investigation. Diagnostics, 2022, 12, 1926.	1.3	13
822	Contouring the accessory parotid gland and major parotid glands as a single organ at risk during nasopharyngeal carcinoma radiotherapy. Frontiers in Oncology, $0,12,12$	1.3	0
824	Intensity-modulated Radiation Therapy and Xerostomia. Journal of the California Dental Association, 2006, 34, 743-748.	0.0	0
825	Machine learning for normal tissue complication probability prediction: Predictive power with versatility and easy implementation. Clinical and Translational Radiation Oncology, 2023, 39, 100595.	0.9	1
826	Dose–volume constraints for headâ€andâ€neck cancer in carbon ion radiotherapy: A literature review. Cancer Medicine, 0, , .	1.3	1
828	Management of symptoms and treatment-related toxicities of head and neck cancers., 2024,, 341-358.		0